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      Abstract 
Introduction: Hypoxia re-oxygenation in kidney transplantation affects the outcome. Hydrogen 
sulphide (H2S), (the newest Gasotransmitter), showed significant protective effect on renal 
transplantation induced IRI. Our objective was to determine if new mitochondria targeted H2S 
donor molecule (AP39) would be more efficacious in protecting renal cells against IRI compared 
to the non-specific H2S donor molecule GYY4137. We hypothesized that AP39 would be more 
potent. 
Methods: in vitro porcine kidney tubular epithelial cells (LCC-PK1) were exposed to warm 
hypoxia, without treatment (Control), with AP39 or GYY4137 followed by re-oxygenation.  
Results: 200nM of AP39 protected the cells and maintained a high viability. AP39 was superior 
to GYY4137. Significant reduction of Apoptosis and ROS were noted in AP39 samples when 
compared to control. Both BCL2 and BID genes did not show any significant changes, compared 
to the control and GYY4137 samples.  
Conclusion: AP39 is protective and superior to GYY4137 in renal IRI. 
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 Chapter 1 
1. Introduction 
1.1.End Stage Renal Disease 
Chronic kidney disease (CKD) - defined as a kidney disease affecting its function and lasting 
more than 3 months- is a major public health problem. Around 7.8 per 1000 patient years in the 
USA develop chronic kidney disease (Kurella & Chertow, 2005). The prevalence of chronic 
kidney disease in Canada, USA and Europe is nearly about the same being around 10 to 11%. 
Late stages of CKD increase the risk of dying from a cardiovascular disease to 4 times the 
average risk. The late stage of chronic kidney disease is known as end stage renal disease 
(ESRD). Such stage of kidney disease requires renal replacement therapy (RRT) as dialysis or if 
possible kidney transplantation.  
The risk of cardiovascular related death in ESRD goes up to 100 times the average risk of the 
general population (Baigent, Burbury & Wheeler, 2000). Patients with ESRD have many 
symptoms that affect their quality of life and increase their lifelong morbidity. Around 50 to 90 
% suffer from fatigue, pruritis, anorexia, pain or constipation. While around 25% to 45 % suffer 
from sleep problems, anxiety, dyspnea, restless leg syndrome, dyspnea or depression (Murtagh, 
et al., 2007). 
Many studies compared renal transplantation to dialysis and the vast majority showed significant 
advantages of transplantation over dialysis (Tonelli, et al., 2011). Transplantation is favorable in 
terms of mortality (Sezer, et al., 2004; Chauveau, et al., 2009), morbidity, hospitalization, 
infections, cardiovascular events (Brunkhorst, et al., 2003; Ward, 2000) and overall quality of 
life (Bajardi, et al., 2003). Transplantation also is the most cost-effective treatment for ESRD 
(Glanton, et al., 2003). The costs of treating patients living on a transplant are indeed by one-
third to one-quarter lower than those spent on dialysis patients (Bruno, et al., 2003). 
Not to mention hypotension during dialysis, the dialysis access (catheter) site complications, the 
electrolyte imbalance and the fatigue after dialysis sessions. Also missing a session or two of 
dialysis has serious consequences that might be life threatening, like fluid overload leading to 
pulmonary edema, electrolyte imbalance (hyperkalemia) leading to arrhythmias or uremic 
encephalopathy with coma.  
 Despite being a survival necessity in these patients, dialysis does not prevent or decrease the 
other complications of ESRD like chronic anemia, bleeding tendency, metabolic bone disease 
(vitamin D deficiency), and immune suppression. All these draw backs and failure of dialysis 
made kidney transplant surgery the only chance for cure and the best treatment option. 
 
1.2.Kidney Transplantation 
Kidney transplantation as discussed previously offers the best survival, disease free survival and 
the most  cost effective treatment for  patients compared to dialysis (Tonelli et al., 2011).  
However the surgical procedure of kidney transplantation is considered a high risk surgery and 
this risk limits its validity for some patients who have many comorbidities. A long list of surgical 
complications with a significant number of which being a serious complication with a 
considerable mortality or morbidity risks. Also the need for immunosuppressing medications that 
has a long list of side effects including risk of cancers, infections and coronary artery disease 
adds to the limitations. One of the most disappointing truths about kidney transplantation is its 
limited durability, especially in the scenario were the transplanted kidney is from a deceased 
donor, which accounts for nearly seventy percent of the kidney transplants in the United States 
and Canada in the current practice. 
Many factors affecting the graft (transplanted kidney) survival were studied with many efforts 
made to prolong graft survival. Among these factors are some uncontrollable variables like 
donors' characteristics and some of the recipients' demographics. 
However, among the factors that are adjustable are the ischemia time of the kidney before being 
transplanted in the recipient.  Limiting the time of ischemia limits the injury induced by ischemia 
and the injury induced by reperfusion after a long period of ischemia. However, due the shortage 
of organs and the long waiting lists of donors the need for more donors had led to the acceptance 
of donors after cardiac death with long ischemia times. 
 
Deceased donors are now constituting the majority of kidney donors for transplantation in many 
countries. According to the organ procurement and transplantation network (OPTN) data, 
deceased donors were the source of 8594 kidneys compared to 5818 from living donors in 2014. 
The available types of donors for kidney transplantation are shown in Figure 1. 
 Donors who meet the criteria for brain death are considered donors after brain death (DBD). 
Donation after cardiac death (DCD) are donors who suffer untreatable brain injuries but do not 
fulfill the criteria for brain death who arrest after withdrawal of ventilator and blood pressure 
support.  
As the control of ischemia time in the deceased cardiac donors is limited by the donors 
condition, organs from such donors showed a higher incidence of the injury known as ischemia 
reperfusion injury (IRI) which eventually can affect the short and long term graft survival. 
(Ponticelli, 2014)(Tojimbara et al., 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1 
 The available types of donors for kidney transplant. DBD: donation after brain death. 
DCD: donation after cardiac death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.3.Ischemia reperfusion Injury and Delayed Graft Function 
(DGF) 
1.3.1.Ischemia Reperfusion Injury 
One of the earliest descriptions of ischemia reperfusion injury (IRI) in whole organ systems was 
in 1975 by Cerra et al. (1975) who demonstrated its importance in canine model in myocardial 
pedicles. They examined the extent of reperfusion injury and found that increased ischemia times 
were associated with increased sub endothelial hemorrhagic necrosis. IRI is a pathophysiological 
process that is inevitable in kidney transplantation, and as will be discussed later, is an important 
contributor to peritransplant renal injury. 
It is not only limited to transplantation, as it also occurs in a wide variety of disease processes 
like myocardial ischemia (Yellon & Hausenloy, 2007) pre renal-renal injury, ischemic 
cerebrovascular accidents, and vaso-occlusive crises of sickle cell anemia to name a few 
(Wallace & Linden, 2010). Ischemia of the transplant organ is quite unique as it has components 
of both warm and cold ischemia, depending upon the organ donor type and can also be quite 
variable in terms of the amount of time that a graft may be exposed to the specific injury 
(Eltzschig & Eckle, 2011). Prolonged IRI can have post-transplant squale, with the primary 
effects being delayed graft function (DGF), which can be deleterious to the graft in the long 
term. 
 
1.3.2.Delayed Graft Function (DGF) 
DGF is the most common complication in the early in-hospital post-transplant period with an 
incidence of 2% to 50% following kidney transplantation (Gjertson, 2000; Ojo, et al., 1997; 
Perico, et al., 2004, Koning, et al., 1995). The exact definition for DGF has been debated by 
experts for some time. According to one review, there were at least 18 different definitions used 
in the literature from 1984 to 2007 in 65 published studies (Yarlagadda, et al., 2008).  
Most common definition used and most accepted is the need for dialysis in the first week after 
transplantation. Other definitions used are ATN proven on biopsy (Preidler, et al., 1996; Sadeghi, 
et al., 2006) failure of serum creatinine to drop 10% or more a day for three consecutive days, 
serum creatinine decreasing by <1.1mg/dl in the first 5 days post-transplant(El-Maghraby et al., 
 2002; Boom, et al., 2000) or a serum creatinine level of 2.5mg/dl or more for up to day 7 post-
transplant (Turkowski-Duhem et al., 2005). 
Kidneys which do not seem to immediately function optimally but still not dysfunctional enough 
to meet one of the criteria above for DGF are labeled as slow graft functioning (SGF) (Humar et 
al., 2002).(Le Dinh et al., 2012). Although some literature require the exclusion of other causes 
of dysfunction in the definition of DGF (other than rejection or IRI), the development of DGF 
may be multifactorial. Rejection, anastomotic complications, vascular thrombosis, fulminant 
disease recurrence and drug nephrotoxicity are examples of these other causes of DGF. The 
typical and most common cause for DGF, however, is IRI which leads to acute tubular necrosis 
(ATN) as the typical histological finding (Lechevallier, 1998; Huraib, 2002; Yarlagadda, 2008). 
Additional evidence suggests that the greater the ischemic time before cold preservation (warm 
ischemia) the kidney goes through, the higher the rate of irreversible cell damage which 
eventually reduces graft survival (Siedlecki, Irish & Brennan, 2011). For that reason all efforts 
should be made to decrease IRI, being the leading cause for DGF. The pathophysiology behind 
IRI causing DGF involves the activation of the immune system which will be discussed in the 
sections below. This early immune system activation may also be the early instigator for acute 
and even chronic rejection process. 
 
1.4.IRI Pathophysiology 
Ischemia reperfusion injury is a result of multiple connected cascades initiated by ischemia and 
directly related to the time of ischemia leading to decreased oxygen tension in the tissue 
(hypoxia). The shortage of oxygen in ischemia is sensed by the polyl hydroxelase (PHD) 
enzyme, as they require O2 as a co factor. The shortage of O2 leads to inhibition of PHD. 
Indirectly the inhibition of PHD leads to the activation of the transcriptional factor, hypoxia- 
induced factors (HIF) and nuclear factor kB (NF-kB) (Eltzschig, 2011). 
The activation of HIF during hypoxia stimulates the production of glycolysis enzymes leading to 
the switch to glycolysis as a source of energy instead of the amino acid oxidation energy source. 
This leads to the utilization of the cytosolic glycogen, releasing less amounts of ATP as well as 
the formation of lactic acid as a result of the anaerobic respiration (Eltzschig, 2011). 
 The subsequent depletion of ATP leads to the inhibition of Na/K ATP dependent channels 
leading to the accumulation of sodium within the intracellular space. Excess amounts of sodium 
inside the cell leads to the influx of water inside the cell leading to cell swelling and with more 
ischemia time more swelling involving the cell organelles, which ultimately lead to cell 
membrane rupture and cell death (necrosis). 
Apoptosis is another manner in which cells die as a result of ischemic injury. The leak of pro-
apoptotic molecules from the mitochondria activates cascades of events leading to apoptosis. 
Opposite to necrosis, apoptosis is characterized by cell shrinkage, cell membrane blebbing, 
nuclear fragmentation and loss of mitochondrial membrane potential (Hotchkiss, et al., 2009). 
The cell injury from ischemia might be reversible as long as it does not exceed a limit of 
intensity and duration. Once it exceeds that limit, restoration of blood (reperfusion) surprisingly 
instead of reversing the damage, induces more injury. The reperfusion injury is the results of 
many events, most of which were preconditioned during the ischemic phase and showed its 
potency mainly during the reperfusion phase (Eltzschig & Eckle, 2011). These events are 
mainly: 
a. The "No reflow phenomena": This phenomena point to the fact of non-restoration or 
blockage of the blood flow to variable parts of the ischemic organ (Cheadle, et al., 2011; 
Leaf, 1973; Summers & Jamison, 1971). During hypoxia, adenylate cyclase activity and 
intracellular cyclic Adenosine monophosphate (cAMP) level drop significantly. This 
results in what is called the endothelial dysfunction syndrome (EDS) (Brodsky, 2002). 
This syndrome is characterized by endothelial cell (EC) swelling, expression of adhesion 
molecules and impaired EC barrier function increasing the vascular permeability (Ogawa, 
et al., 1992; Ogawa, 1990). The resulting leaky vessels then allow fluid and cells to 
infiltrate the surrounding tissues (Flores, et al, 1972; Kelly, et al., 1994; Ogawa, et al., 
1992). The endothelial syndrome is the major contributing pathophysiology leading to the 
no reflow phenomena: The swelling of the ECs together with the tissue edema (caused by 
the leakage of fluids and cells through the over-permeable vessel walls) causes a luminal 
and extra luminal narrowing of the affected vessels respectively. This narrowing in the 
end arterioles is enough to block the perfusion to the tissue area supplied by that arteriole. 
The expression of adhesion molecules (as part of the EDS) promotes the adhesion of 
 platelets and inflammatory leukocytes to the endothelium causing micro thrombi, again 
blocking the terminal feeding vessels.  
b. Sterile inflammation and the immune system: Despite the fact that IRI typically occurs in 
a sterile environment, activation of innate and adaptive immune system contributes to a 
significant part of the injury. 
Cell death occurring during ischemia and during reperfusion releases multiple cell 
components and intracellular products into the extracellular space. These are potent 
chemokines and cytokines that initiate multiple cascades leading to a destructive immune 
response presented by a sterile type of inflammation. Early in reperfusion, once the 
circulation reaches parts of the ischemic organ, these chemokines and cytokines diffuse 
through the circulation recruiting inflammatory cells and activating more of the pro-
inflammatory cascades. Among the early components of the immune system activated are 
the pattern-recognition receptors known as toll-like receptors (TLRs) (Thurman, 2003). 
The TLRs once activated, they initiate a signaling cascade of cytokines expression that 
facilitates the bridging of the innate and adaptive immune systems (Carroll & Holers, 
2005; Chen & Nunez, 2010a). The over expression of adhesion molecules like E-selectin 
and intercellular adhesion molecule-1 (ICAM-1) on ECs (as part of the EDS during the 
ischemic phase) facilitates the adhesion of the inflammatory cells brought up by 
reperfusion. These adhered inflammatory cells find its way infiltrating the tissue to cause 
inflammation. 
c. The cellular cytotoxic effects of reperfusion: At the cellular level, reperfusion restores the 
pH of the cells which was found to be cause more injury through different mechanisms: 
1- Restoration of pH leads to re-opening of the mitochondrial permeability transition 
pores (MPTPs). The MPTPs close in ischemia induced acidosis (low pH) as a protective 
mechanism. Once the pH is restored in reperfusion, it facilitates the injurious 
uncontrolled influx of previously accumulating cytosolic Ca++ and ROS into the 
mitochondria, causing an irreversible mitochondrial damage. 2- Activates Na/ Ca++ 
exchange, leading to more accumulation of intracellular Ca++ and cell death. 3- 
Phospholipases and other destructive enzymes released during ischemia are inactivated in 
acidotic environments and reactivated once acidosis is resolved 
  
 
1.5.IRI as a sterile inflammation and the immune system 
The recipient immune system is a constant threat to graft survival despite the recent advances in 
pre transplant immune workup, preparation, prevention and treatment of the sterile type of 
inflammation seems to play a significant role in limiting IRI. Interestingly, IRI induced 
inflammation and infection induced inflammation share some similar mechanisms (Chen & 
Nunez, 2010b). Similar to ligands binding to Toll like receptors (TLR) in initiating the 
inflammatory response when it detects a microorganism, there are special damage associated 
molecular patterns (DAMPs) that act as ligands in cases of the sterile inflammation in IRI that 
also bind to and activate TLR and their downstream effector pathways. Some examples of 
endogenous DAMPs which can activate TLR include high-mobility group box 1 (HMGB1), Heat 
shock protein (HSP) fibronectin, hyaluronan, and biglycan are examples of DAMPs that can 
activate TLR (Wu, et al., 2007). 
These endogenous DAMPs are released from the dead or dying cells into the extracellular space 
(Iyer, et al., 2009; McDonald, et al., 2010). Activation of TLR leads to the release of cytokines, 
chemokines and other inflammatory mediators which recruit more inflammatory cells (Wu et al., 
2007). Recruited inflammatory cells release more ROS leading t further tissue inflammation and 
subsequent damage. While TLR3 was activated by RNA released from dead cells (Cavassani et 
al., 2008), both TLR2 and TLR4 TLR2 was proven to be over expressed in response to hypoxia 
(Kuhlicke, et al., 2007) (oxidative stress) as well as enhance the response of cells of the innate 
immune system. In a TLR4 -/- chimeric mice, IRI was proven to be less in terms of serum 
creatinine and histological findings (Wu, et al., 2007). 
Neutrophils - representing the humeral part of the innate immune system - are the first to present 
in the inflammation site and to modulate the inflammation following transplantation and most if 
not all inflammatory reactions. As part of the adaptive immune system, both T cells and B cells 
have been shown to play a role in IRI. Trials evaluating the role of T cells and B cells in IRI 
demonstrated that either the absence of one or both may be protective against IRI (Mehrabi, 
2007). 
 The role of T-cell activation is important in IRI. In fact with respect to CD4 T-cells, the Th 1 
pathway was found to participate in IRI while Th2 pathway was found to be protective (Burne, et 
al., 2001; Fiorina, et al., 2006; Yang, et al., 2006). Unfortunately, the exact mechanism behind its 
activation is not well understood. T-cells are activated via an antigen dependent or non-antigen 
dependent pathway. (Satpute, et al., 2009; Shen, et al., 2009) 
Cytokines, chemokines, ROS as well as complement can all activate T cells. This becomes 
increasingly important when we consider the degree of inflammation with resides especially in 
DCD donation (Boros & Bromberg, 2006; Friedewald & Rabb, 2004). Once the T-cell is 
activated in IRI it can further lead to enhanced neutrophil recruitment and releases IFNɣ which is 
an important cytokine of inflammation (Shigematsu, Wolf & Granger, 2002; Yang, et al., 2006). 
 
1.6.Methods of Limiting Transplant-induced IRI 
The field of solid organ transplantation is still lacking in methods, medications and or products 
that can prevent or limit IRI. Current therapeutic measures at reducing IRI include the use of 
cold storage (Jochmans, 2010; Belzer & Southard, 1988), pulsatile mechanical perfusion (Deng, 
et al., 2013), the use of various preservation solutions (Groenewoud & Thorogood, 1992) and 
strong immunosuppressive medication (Mourad, et al., 2012; Mehrabi, et al., 2007; Faure, et al., 
2004; Warnecke, et al., 2012). Most recently, the use of endogenously derived gasotransmitters 
have been shown to provide some relief for tissue IRI (Strüber, et al., 1999).  
 
1.7.Hydrogen Sulphide as a Gasotransmitter 
There are currently three known, endogenous produced gaseous molecules with physiological 
and pathophysiological properties—these molecules have been termed “gasotransmitters”. 
Gasotransmitters are lipid soluble, endogenously produced, and freely permeate the plasma 
membrane of a cell to pass the message directly to an intracellular target (Wang, 2002; Wang, 
2003b). If a gas molecule, has significant physiological effects, controlled production by 
endogenous enzymatic reactions, specific inactivation mechanisms and specific cellular targets, 
it is considered to meet the criteria created by Wang and later on modified by Linden et al for 
gasotransmeters (Linden, et al., 2010).  
 Gasotransmitters do not bind to plasma membrane receptors, they actually diffuse into adjacent 
cells and start downstream function once they reach their multitude of targets. Also instead of 
being stored in vesicular structures, gasotransmitters must be resynthesized as needed. The three 
members of the gasotransmitter family are nitric oxide (NO), carbon monoxide (CO) and 
hydrogen sulfide (H2S). 
NO was the first gasotransmitter to be recognized as a signaling molecule. That was initiated 
after the discovery of its potent smooth muscle relaxation through the actions of acetylcholine 
(FURCHGOTT, & ZAWADZKI, 1980). H2S is the newest addition to the gasotransmiter family 
(Wang, 2002). Hydrogen sulfide is studied less than the other members of gasotransmitters 
(Bucci et al., 2012) with much more to be discovered about this molecule. 
All three of the gasotransmitters have been found to share effects including vasodilatory, anti-
inflammatory, anti-oxidant properties (Mustafa, et al., 2009). The way these gas transmitters 
interact or link is still not well understood. For example it was found that NO induces the 
production of H2S in vascular tissue by increasing both the expression and activity of one of the 
enzymes that produces H2S (Zhao, Zhang, Lu, & Wang, 2001b). 
All three gas transmitters were studied in the field of ischemia reperfusion injury extensively and 
the fact that these agents have many potentially cytoprotective, anti-inflammatory and perfusion 
improving effects, (features that perfectly suited the field of transplant) made these molecules 
attractive to the field of transplant. Perhaps the feature of hibernation and metabolism slowing 
effects of H2S made this molecule even more interesting in such a field -organ preservation for 
transplant- where metabolism slowing methods already showed significant benefits (Belzer & 
Southard, 1988).  
 
1.8.Hydrogen Sulphide (H2S) 
1.8.1.History of H2S  
It is believed that H2S was described as one of the gases of putrefaction by Johann Baptista van 
Helmont (1579–1644) who extensivly studied gases and earned the honor of being known as 'the 
real father of pneumatic chemistry (Leicester & Klickstein, 1952). The Italian physician 
Bernardino Ramazzini in 1713 described a disease of cleaners of Privies and Cesspits related to 
an unknown acid that is produced in that working environment causing eye inflammation.  
 In 1750 Carl Wilhelm Scheele treated ferrous sulfide with a mineral acid, and he noted the 
resulting stinking odor of H2S which he called sulfur air, and for that he was the 1st to produce it 
in the lab. Later in 1777 reported cases in sewers of Paris with eye inflammation and others with 
asphyxia related death were also related to the same acid bringing its significance and awareness 
to a higher level. When Warenycia and Goodwin were studying the toxic effects of H2S in rat 
and human brain in 1989, they found that detectable amounts of H2S were produced 
endogenously (Warenycia et al., 1989). In 1996, Abe et al (Abe & Kimura, 1996) suggested that 
H2S was an endogenous neuromodulator, as they showed that physiological concentrations of 
H2S enhanced NMDA receptor-mediated responses and aided in the induction of hippocampal 
long-term potentiation. 
Shortly after, Hosoki et al (1997a) reported that an enzyme, which produces H2S, is present in 
the ileum, portal vein, and thoracic aorta and proposed that H2S may be an endogenous smooth 
muscle relaxant. The recent interest in H2S research mostly started after the finding that H2S 
dilates rat blood vessels both in vitro and in vivo (Zhong, et al., 2003; Du, Yan & Tang, 2003). 
 
1.8.2.Chemical features, toxicity and Sources of H2S 
Hydrogen sulfide H2S is a colorless gas with a rotten egg smell. Liquid in very cold temperatures 
or very high pressure with a melting temperature of -85o C and a boiling temperature of -60.7o C 
(http://www.ccohs.ca). It is flammable at a concentration range of 4-46% with an autignition 
temperature of 260oC-290oC. Its structural formula is H-S-H (www.ccohs.ca). Cold dry air 
prolongs the half-life of H2S while high temperatures increase the solubility of H2S. 
H2S can be detectable by its odor at levels as low as 00.47 ppm. Eye irritation and damage can 
occur with levels as low as (10-20ppm) and (50-100) respectively. Higher doses of 200- 500 ppm 
leads to pulmonary edema, nervous system hyper stimulation, respiratory failure and death in 4- 
6hr. A dose of 800ppm can kill 50% of humans in 5min period and this is known as the lethal 
concentration (LC50). The longer the exposure and the higher concentration the more sever and 
irreversible is the injury. A level of 1000ppm can lead to immediate collapse after a single breath 
(www.newworldencyclopedia.org). Thus the threshold limit value for its presence in the 
workplace according to the American Conference of Industrial Hygienists was set not to exceed 
 10 parts per million (ppm) of hydrogen sulfide in air for 8hr/day for 5 days/week 
(www.acgih.org).  
The mechanism behind H2S toxic effects is not fully understood but the main cellular effect of 
H2S in toxicity is by inhibiting cytochrome C, inhibiting oxygen consumption by mitochondrial 
cytochrome oxidase (Cooper & Brown, 2008) and uncouples the oxidative phosphorylation and 
by that inhibits the mitochondrial respiration mechanism and ATP production. (Dorman et al., 
2002; Guo et al., 2012a) Another related mechanism is the through depletion of Glutathione 
(GSH) which is a potent cytoprotective antioxidant (Sparatore, et al., 2011; Shan, et al., 1993).  
In nature H2S is found in gases of Volcanos, Salt mines, water swamps, undersea vents, lakes, 
stagnant sewage (Kresse, et al., 2007; Mitchell, et al., 2001). It also can be produced by the 
breakdown of organic matter and human/ animal wastes (like in sewage). H2S may collect in 
many areas in the surrounding city environments especially lower leveled, poorly ventilated, 
closed areas such as basements, manholes, sewer lines and underground telephone and electrical 
vaults (Stellman, 1998).  
 
1.8.3.H2S in our body 
As mentioned above in the section of H2S history it was found to be produced endogenously late 
in the 1980's. The H2S in our body (in normal physiological status with a temperature of 37o C 
and a pH of 7.4) is mainly (80%) in the form of HS- and < 20% is in the dissociated form H2S 
(Dorman et al., 2002; Dombkowski, et al., 2004). Zhao et al reported that H2S concentration in 
humans plasma ranges between 45-300uM (Zhao, et al., 2001b; Qingyou, et al., 2004). 
Others did report that concentrations of H2S in vertebrate blood varied between 30-100uM, while 
in the brain showed higher concentrations ranging between 50-160uM (Abe & Kimura, 1996; 
Dello Russo, et al., 2000; WANG, 2002). However, there have been many arguments 
demonstrating that these concentrations cannot be correct (Olson, 2009; Olson, 2011a; Olson, 
2011b).  
Olsen (2012) discussed and summarized this debatable issue in his review "A Practical Look at 
the Chemistry and Biology of Hydrogen Sulfide" (Olsen, 2012). He pointed that the previously 
reported concentrations showed huge differences when measured using different H2S 
measurement methods. Also some of these high concentrations theoretically can be only 
 acquired by the exposure to toxic levels of H2S. The need to determine the real physiological 
concentrations of H2S in blood and tissues -if any- still yet to be determined. This is largely 
depends on identifying the best method for measuring H2S in different biological tissues and 
fluids. 
 
1.8.4.Sources and Production of H2S in Humans and Most Mammals 
H2S is produced in our bodies through enzymatic and non-enzymatic pathways. The enzymatic 
pathway produces H2S from the amino acids cysteine, cystathionine and homocysteine. The 3 
enzymes capable of producing H2S in humans are: 1) cystathionine gamma lyase (CSE), 2) 
Cystathionine beta synthase and 3) 3 Mercaptopyruvate sulfartransferes (3MST). Cysteine is an 
essential precursor for all of these enzymatic pathways. 
CBS and CSE are considered the major ones with more extensive studies with the cofactor being 
active vitamin B6 (pyridoxal 5' -phosphate (PLP)). Both CBS and CSE are mainly localized to 
the cytosol while 3MST is more found in the mitochondria. CBS catalyze the transsulferation of 
homocysteine to cystathionine. Then both CBS and CSE then metabolize cystathionine in the 
production of H2S.  
1.8.4.1.Production of H2S 
The non-enzymatic pathway releases a small amount of endogenous H2S in humans. Sulfur is 
reduced by the reducing equivalents from glucose oxidation to produce H2S. The source of the 
reducible sulfur is mainly elemental (Benavides et al., 2007).  
The enzymatic pathway, the major pathway of H2S production in our body and majority of 
mammals. 
Three enzymes are known to be responsible for the majority of H2S production with different 
concentrations in different tissues. These are :Cystathionine β-synthase (CBS), Cystathionine γ- 
lyase (CSE) and 3-mercaptopyruvate sulfotransferase (3MST). (Hosoki, Matsuki, & Kimura, 
1997)(Abe & Kimura, 1996) 
 
a. CBS: 
In humans CBS is 63- kDa subunits Homotetramor, with each subunit consist of 551 amino acids 
(Kery, et al., 1994). CBS utilize cysteine or homocysteine to produce H2S. Mainly available in 
 the cytoplasm CBS is the dominant enzyme producing H2S in the brain, equal to CSE in the 
skeletal muscles, gastrointestinal and penile smooth muscles (d'Emmanuele di Villa Bianca et al., 
2009; Fiorucci et al., 2005), while CSE dominates in the cardiovascular system (Awata, 
Nakayama, Suzuki, Sugahara, & Kodama, 1995; Lowicka & Beltowski, 2007).  
Without CBS homocysteine accumulates in the tissue as it cannot be catalyzed through the 
transsulfuration pathway (Jhee & Kruger, 2005). Genetic deletion of CBS results in markedly 
elevated levels of homocysteine "Homocystinuria". This disease is marked with significant 
cardiovascular impairment. CBS gene is located on chromosome 21 in humans. More than 150 
gene mutations of CBS has been identified in the disease of homocystinuria. (Kruger et al., 2000) 
CBS heme has a very strong affinity to CO, which physiologically inhibits CBS. This inhibition 
might explain the cerebral vasodilation effect of CO. 
 
b. CSE 
Cystathionine ɣ-lyase with either (CGL) or more common (CSE). Measuring about 45 kDa. 
Located on human chromosome 1. 
CSE like CBS, produces H2S from cysteine and homocysteine. 
The deficiency of CSE leads to accumulation of cystathionine (hypercystathionenemia) and the 
excess of excretion in the urine (cystathioninuria) (Renga, 2011). CSE is now believed to be the 
principole enzyme responsible for H2S production in the peripheral tissue and of our interest in 
the kidney (Paul & Snyder, 2012). 
 
c. 3MST 
3 mercaptopyruvate sulfotransferase together with Cysteine amino transferase (CAT) can 
produce H2S from cysteine when α-ketoglutarate is present. 
Both 3MST and CAT are found in the Mitochondria and cytcole. In order to reach maximum 
activity, 3-MST needs very high pH levels 3MST utilizes the alpha ketogluterate produced by 
CAT to produce H2S. The H2S produced by 3-MST is mainly in the form of sulfane sulfur, 
which is then stored rather than used (Hu, et al., 2011). 
In the kidney H2S is produced by all three enzymes with CSE playing the major role (Stipanuk 
and Beck, 1982). CBS, CSE and 3-MST are primarily present in proximal tubules within the 
 renal cortex (House, et al, 1997; Nagahara, et al, 1998; Yamomoto, et al, 2013). CBS was 
established to primarily be localized in the proximal convoluted tubule in the outer cortex 
whereas CSE to be localized mostly in the proximal straight tubule in the inner cortex and outer 
medulla (Ishii, et al, 2004; Li, et al, 2006). 
 
1.8.4.2.Fate of H2S 
Concentrations of H2S in many studies showed to be rapidly balancing. Even after the 
administration of exogenous H2S sufficient to cause recognizable effects, the levels rapidly 
equalized back to its normal levels. This stability of H2S levels is expected with all the potent 
pathways that work on controlling its levels. This balance also is meant to avoid the toxic effects 
of H2S accumulation which could be detrimental to life. There are several pathways involved in 
H2S breakdown and elimination (Bhatia, et al., 2012).  
Oxidation: Oxidation is the main method of H2S metabolism. Intracellular, mitochondria plays a 
major role in controlling H2S metabolism. As significant amount of H2S is rapidly oxidized by 
the mitochondria into sulfate (SO4 2−) and sulfite (SO32) (Li, Rose, & Moore, 2011).  
Methylation: Another less important metabolism pathway is the methylation that takes place in 
the cytosol. Methylation of H2S by thiol-S-methytransferase to yield methanethiol and dimethyl 
sulfide represents another less important mechanism of H2S degradation, and therefore accounts 
for a smaller amount of H2S (Levitt, et al., 1999). 
Other: other known pathways for the metabolism of H2S is by reacting with disulfide containing 
proteins or metalloproteins like cytochrome C.(Guo et al., 2012a) 
Also being a potent reducing agent, significant amount of H2S is utilized in scavenging and 
reaction with the produced ROS (Li et al., 2011). Scavengers of H2S like Methemoglobin or 
oxidized glutathione also play a role in the consumption of H2S (Fiorucci et al., 2007). 
Methemoglobinemia is sometimes induced by 3% sodium nitrite for the treatment of H2S 
toxicity to form sulfhaemoglobin.  
Majority of H2S oxidation takes place in the liver to form sulfate which is then excreted in the 
urine as free or conjugated sulfate (Beauchamp, et al., 1984). A small percentage of the H2S 
produced by the fecal bacteria in the colon is excreted in feces according to the study on rats 
(Levitt, Springfield, Furne, Koenig, & Suarez, 2002). 
  
1.9.H2S protective mechanisms in ischemia–reperfusion 
In vivo and Ex-vivo studies proved H2S protection against IRI in the lung (Z. Fu, Liu, Geng, 
Fang, & Tang, 2008), the liver (Jha, Calvert, Duranski, Ramachandran, & Lefer, 2008), the heart 
(Elrod et al., 2007a; Sodha et al., 2008) and – most relevant to this thesis- the kidney (Tripatara 
et al., 2008).  
 
1.9.1.Antioxidant Effects of H2S 
Oxidants or cytotoxic Reactive Oxygen species (ROS) are free radicles and reactive molecules 
that are generated by molecular oxygen. Molecular Oxygen itself is a stable biradicle while 
oxygen atom is highly unstable. The Oxygen atom has two unpaired electrons in separate orbits 
making it vulnerable to release ROS. These ROS are generated during the mitochondrial 
transport chain of aerobic respiration. ROS are either radicals or non-radicals. Radicles include 
superoxide radical anion (•O2-) hydroxyl radical (HO•) and peroxyl radicals (ROO•) while non-
radical derivatives are like hydrogen peroxide (H2O2), peroxynitrite (ONNO-) and hypochlorous 
acid (HOCL). 
Important physiological functions of ROS were recently identified. These physiological roles 
serve in vascular tone modulation, endothelial function and Induction of host defense (Droge, 
2002; Mueller, Laude, McNally, & Harrison, 2005; Pawlak, Naumnik, Brzosko, Pawlak, & 
Mysliwiec, 2004; Touyz & Schiffrin, 2004). The Excess of ROS is where its pathophysiological 
role overcomes its physiological function. ROS has the potential to destruct the cell membrane, 
cell proteins and other cellular structures. ROS in addition to its direct destructive potential, ROS 
induce damage by activating redox- sensitive signaling pathways (Ushio-Fukai, Alexander, 
Akers, & Griendling, 1998).  
Among these activated signaling pathways are mitogen-activated protein kinases (MAPK) (X. 
Wang et al., 2011) and transcription factors (NFκB and HIF-1) (Chandel et al., 2000; Narayanan 
et al., 2014). ROS also increase intracellular-free Ca2
+ concentration and upregulate proto-
oncogene, profibrotic and pro-inflammatory gene express (Griendling, Sorescu, Lassegue, & 
Ushio-Fukai, 2000; Hernandez-Fonseca, Cardenas-Rodriguez, Pedraza-Chaverri, & Massieu, 
2008; Law et al., 2013). In the physiologic status the cells manage to detoxify ROS by the 
 detoxifying mechanisms. During hypoxia the excess production of ROS leads to cell destruction 
and signals cascades leading to cell necrosis. 
Excess ROS accumulation intracellular also prolongs the activation of c-Jun-N-terminal kinase 
gene which promotes apoptosis (Nakano et al., 2006). For that the cell has many mechanisms to 
detoxify ROS. These are through a variety of enzymes like Glutathione peroxidase and 
Superoxide Dismutase (SOD) (McCord & Fridovich, 1968) and non-enzymatic molecules: like 
Glutathione (GSH), Vitamin C, vitamin E and others. Glutathione is considered among the most 
important defense mechanisms against ROS. Depletion of intracellular GSH leads to 
accumulation of ROS and cell damage (Wang, 2012). 
ROS plays a major role in the injury induced by ischemia reperfusion. Controlling the production 
of ROS has been an interest in hope to counteract cell damage in a variety of pathological 
processes. In many studies H2S was proven as a potent anti-oxidant. H2S anti-oxidant effects are 
both direct and in direct. Direct effects of H2S on ROS are explained by acting as a strong 
reducing agent. It directly scavenge a number of known potent ROS like peroxinitrite, 1-methyl-
4-phenylpyridinium (MPP+) and NO (Schreier et al., 2010; Whiteman et al., 2006) (Whiteman et 
al., 2004a). 
Whiteman et al. using an in vitro model of human neuroepithelioma cell line showed that H2S 
inhibits the cytotoxic effects of hydroxychloric acid (HOCl). H2S also reduced the HOCl induced 
protein oxidation and lipid peroxidation (Whiteman et al., 2005). In the same in vitro model of 
human neuroepithelioma H2S also blocked the cytotoxic effects of peroxinitrite and its 
intracellular protein nitration and oxidation (Whiteman et al., 2004b), lipid hydro peroxides 
(LOOH) are non-radical intermediates, and once catalyzed by single electron reduction it triggers 
the free radical chain mechanism of lipid peroxidation. H2S treatment was able to destroy 50% of 
LOOH in oxidized Lipodensity lipoprotein (oxLDL). (Muellner et al., 2009) 
H2S is a strong reducing agent, being able to react with multiple oxidant stressors including 
superoxide radical anion (Mitsuhashi et al., 2005), hydrogen peroxide, (Geng et al., 2004) and 
peroxynitrite (Whiteman et al., 2004a). The indirect anti-oxidant effects of H2S is by up 
regulating and increasing the level of Glutathione (GSH) and Superoxide dismutase (SOD) 
(Kimura, Dargusch, Schubert, & Kimura, 2006). 
 
 1.9.2.Anti-apoptotic effects of H2S 
Xu et al. studied the effect of H2S on apoptosis during oxidative stress of hemorrhagic shock in a 
rat model. They concluded that H2S administration protected rat lungs against inflammation by 
suppressing oxidative stress and the Fas/FasL apoptotic signaling pathway as well as attenuating 
the expression of pro-apoptotic proteins FADD, active-caspase 3, active-caspase 8, Bax, and 
increasing the expression of Bcl-2. Sodium hydrosulfide alleviates lung inflammation and cell 
apoptosis following resuscitated hemorrhagic shock in rats. 
Another rat model of IRI by Sivarajah A1et al. demonstrated that H2S attenuates both the 
decrease in Bcl2 expression as well as the increase in caspase 9 activity in the myocardium 
(Sivarajah, et al., 2009). Many of the pro-apoptotic Bcl-2 proteins like Bid, Bax and Bak play a 
major role in apoptosis. Bid binds to the external membrane of the mitochondria, activating the 
other proapoptotic proteins Bax and Bak (Crow, Mani, Nam, & Kitsis, 2004). Release of 
cytochrome c from the mitochondria into the cytoplasm (Kluck, Bossy-Wetzel, Green, & 
Newmeyer, 1997; X. Liu, Kim, Yang, Jemmerson, & Wang, 1996) is mainly triggered by both 
Bax and Bak activation. Cytochrome c after that initiates various caspases activations powerful 
enough to initiate apoptosis (Du, et al., 2000; Verhagen, et al., 2000). 
Apoptosis inducing factor (AIF) a caspase independent pro-apoptotic protein. Is located in the 
space between the inner and outer mitochondrial membranes. It is released into the cytoplasm 
and into the nucleus. It condensates the chromatin within the nucleus and fragments the DNA 
(Daugas et al., 2000). Another important cytosol protein important in IRI induced apoptosis and 
affected by H2S is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). 
This transcriptional factor once activated by different stimuli is capable of rapidly binding to the 
DNA and inducing various gene transcriptions responsible for many cellular events including 
apoptosis.  
In an IRI model, Biermann et al showed that H2S inhibits apoptosis by inhibiting NF-kB and 
limiting its binding to DNA. That inhibiting effect of H2S on NF-KB was only encountered after 
IRI (Biermann, et al., 2011). In other studies H2S enhanced the binding of NF-κB to the DNA 
but still that resulted in decreased apoptosis. This anti-apoptotic influence of NF-κB was 
significantly diminished in CSE deleted mice (Sen, et al., 2012). As the mitochondria are 
believed to be the key in apoptosis, controlling it seems to enhance or decrease apoptosis (Wang, 
2012). Since H2S protects the Mitochondria and prevent its destruction through many 
 mechanisms -will be discussed later in this chapter- It should be true that H2S must play some 
role in protecting against apoptosis. 
 
1.9.3.Vasorelaxant effects of H2S 
As described in the mechanism of injury of IRI previously, blood vessels play an important role 
in IRI. In fact most of the IRI models ischemia is induced by the severe constriction or blockage 
of the vessels (Vincent, et al., 2011). During reperfusion a balanced vascular tone to maintain 
enough blood pressure but still relaxed enough to allow sufficient amount of blood flow 
supplying nutrients and oxygen to the tissue is essential.(Eltzschig & Eckle, 2011) 
The involvement of gasotransmitters, in the regulation of vascular tone was first noted with the 
discovery of NO physiological roles. Recently H2S and NO were found to act in a way of 
synergism in inducing vasorelaxation in vascular smooth muscle cells (VSMCs) (Hosoki et al, 
1997). In 1997 Hosoki et al demonstrated that exogenous H2S relaxed rat aortic tissues in vitro 
(Hosoki, Matsiki, & Kimura, 1997b). When exogenous H2S proved to induce hypotension, it 
raised the hypothesis that endogenous H2S must play a role in regulating the tone of vessels in 
the human body. 
The main source of H2S in the vascular walls is the enzymatic pathway of CSE. That was 
demonstrated clearly when Yang et al. CSE knockout mice showed low levels of H2S in their 
vascular tissue and as a result of low H2S levels, the mice developed significant hypertension 
(Yang et al., 2008). Majority of studies on the vascular system showed H2S to produce 
vasorelaxation (Wang, 2009). Other considers H2S function on vascular smooth muscles to be 
biphasic. As it causes vasorelaxation in high doses (100µM- 1,600 µM) while low concentrations 
(10-100 µM) causes' vasoconstriction (Ali et al., 2006; Lim, Liu, Khin, & Bian, 2008). 
Mechanism by which H2S induces this response of vasodilation is not fully understood but many 
mechanisms were proven to induce it. Trying to define the mechanisms behind the vasorelaxant 
effects of H2S, the activation K+ channels seems to play the major role. The fact that H2S plays a 
role in regulating the vascular tone is one of the evidences to explain H2S potency in preventing 
IRI. Like the other gasotransmitters NO and CO, H2S showed potent vasorelaxant effects. When 
considering site of release, target tissues and mechanism of action, H2S is significantly different 
than the other gasotransmitters.  
 NO and CO mediate vasorelaxation by increasing the cellular cGMP activity and/or stimulating 
KCa channels in vascular smooth muscle cells (SMCs) (Zhao et al., 2001b). Zhao et al. studied 
the effects of H2S in vivo and in vitro while looking for the effects of H2S on the cardiovascular 
system. Intravenous injection of H2S provoked a transient but significant decrease in mean 
arterial blood pressure. They concluded that the drop in blood pressure was mainly due to the 
vascular tone since heart rate was not affected. Similar effect was induced when the KATP 
channel opener pinacidil was used. While on the other side the effect of H2S was blocked when 
the KATP channel blocker Glibenclamide was used. This last also showed that H2S in 
physiological concentration rate is believed to play a role in vasorelaxation. (Zhao, et al., 2001a) 
H2S opens the KATP channels causing hyperpolarization of the SMCs and impairing the voltage 
dependent Ca++ channels (Wang, 2009). When Nelson et al. used blockers for different K 
channels (KATP, KCa++ and Kv channels) trying to identify the role of each, all showed to play a 
role in the relaxation of the vessels walls. In a step towards identifying the relation between NO 
and H2S similar vasorelaxation effect. 
NO was found to enhance the concentration of H2S in the vascular tissue via increasing the 
activity of CSE either directly or by increasing the activity of cGMP- dependent protein kinase 
and up regulating the expression of CSE with a mechanism that is still unclear (Zhao et al., 
2001b). In the other hand, H2S is believed to facilitate the release of NO and other EDHF (Tang 
et al., 2013). Unlike NO and CO, H2S vasorelaxant effect showed to be independent of the 
activation of cGMP (Tang et al., 2013). 
H2S also is unique as it is synthesized in both endothelial cells (EC) and smooth muscle cells 
(SMC). CSE being the major enzyme responsible for H2S production in SMCs while 3MST/CAT 
enzymatic pathway produces H2S in the ECs (Shibuya, et al., 2009). H2S released from both 
SMCs and ECs and opens the K ATP channels, causing hyperpolarization of the SMCs of the 
vessels wall and impairing the voltage dependent Ca++ channels (Wang, 2009). 
This by itself qualifies H2S as an endothelial derived hyperpolarizing factor (EDHF). H2S also 
releases other EDHF from the ECs. While NO is an EDHF in large arteries, H2S is believed to be 
an EDHF of small resistance vessels that affects blood pressure. (Mustafa et al., 2011; Nagao, 
Illiano, & Vanhoutte, 1992; Urakami-Harasawa, et al., 1997; Wang, 2003b). It is suggested that 
the targets of H2S on SMCs and ECs are different. In ECs H2S acts on Kca
++ channels which 
hyperpolarizes the endothelial cell itself and releases other vasoactive substances (Qiu & 
 Quilley, 2001), while H2S targets ATP dependent K
+ channels on SMCs, hyperpolarizing the 
SMCs themselves (Wang, 2012). New data suggest that H2S is an endothelial derived 
hyperpolarizing factor (EDHF). CSE being the major enzyme responsible for H2S production in 
SMCs while 3MST/CAT enzymatic pathway produces H2S in the ECs (Shibuya, et al., 2009). As 
NO is an EDHF in large arteries, H2S is believed to be an EDHF of small resistance arteries 
(Wang, 2003a; Wang, 2009). 
It is hard to tell wither the SMCs H2S or the ECs H2S plays the major role in the vasorelaxant 
effect, but it is suggested that the targets of H2S on SMCs and ECs are different. And that the 
target of H2S on Endothelial cells is KCa
++ channeles which hyperpolarizes the endothelial cell 
itself and releases other vasoactive substances (Qiu & Quilley, 2001; Wang, 2012). While H2S 
targets ATP dependent K+ channels on SMCs, hyperpolarizing the same cells –SMCs- (Wang, 
2012). Taking into consideration that ATP dependent K channels is the major contributor to H2S 
vasorelaxant effect, SMCs role is much more significant than the endothelial cells as an end 
target of H2S vasorelaxation.  
Another suggested mechanism of H2S vasorelaxation is by part related to its anti oxidant effects. 
H2S reduces the availability of H2O2 (Meng et al., 2007) which is a potent ROS. H2O2 was 
proposed to be an EDHF itself (Shimokawa & Matoba, 2004; You, et al., 2005). Alternative 
mechanisms, that might contribute to its vasorelxant effects is its direct inhibition of ECs 
angiotension-converting enzyme. 
 
1.9.4.Anti inflammatory effects of H2S 
The increased production of H2S during inflammation reflects that it must have a role. 
Controversy in the protective versus harmful effects of H2S in many fields exists, and it is most 
conflicting in the field of inflammation. The general principle understood and agreed upon 
widely states that H2S effects are dose dependent, as high concentrations induces toxic effects 
(Cheung, Peng, Chen, Moore, & Whiteman, 2007)  while low doses can be protective most of 
the time (Elrod et al., 2007b; Jha et al., 2008; Sodha et al., 2008). 
The effects of H2S are also - to some degree - cell specific and dependent on the experiment's 
cell conditioning (Rose et al., 2005). As many trials proved that H2S functions as an anti-
inflammatory, almost as many proved that it promotes inflammation. Here we will discuss the 
 anti-inflammatory role as it is most relevant to the subject of this thesis. Many mechanisms were 
supported by experimental evidence on the protective effects of H2S as an anti-inflammatory 
agent. Tissue edema, one of the hallmarks of inflammation that results from leaky vessels and 
cellular tissue infiltration. In IRI it seems to play an important role in the No reflow phenomena 
as mentioned in the IRI mechanism section above.  
Exogenous H2S decreased edema, probably due to inhibition of plasma and inflammatory cells 
leakage, while inhibitors of H2S enzymatic production increased the development of edema in 
inflammatory conditions (Zanardo et al., 2006). H2S induced some anti proliferative effects on T-
cells (Valitutti, Castellino, & Musiani, 1990) which for some extent limits the inflammatory 
response. Another anti-inflammatory effect of H2S that affects the leukocytes is its ability to 
induce apoptosis in poly morphonuclear (PMN) cells (Mariggio et al., 1998). 
Also H2S is known as a modulator for leukocyte adherence to the endothelium of the vessels. 
The adherence of leukocytes to the walls of the vessels facilitates its infiltration into the tissues 
to induce inflammation. (J. Wallace, 2007) H2S donors decreased leukocyte adhesion induced by 
both Asetylsalysilic Acid-induced and Formyl-Methionyl-Leucyl-Phenylalanine (fMLP), while 
inhibitors of H2S production promote leukocyte adhesion (Wallace, 2007). 
Also the leukocyte rolling, which is an essential step proceeding the leukocyte tissue infiltration, 
was inhibited by H2S during IRI (Yusof, et al., 2009). Inhibition of H2S production was proven 
to increase the rate adherence of the inflammatory cells to the mesenteric vascular endothelium 
of rats (Zanardo et al., 2006). The mechanisms behind H2S modulation of leukocytes adhesion 
are not fully understood. Evidence supports that H2S suppresses intercellular adhesion molecule-
1 (ICAM-1) on endothelial cells and leukocyte function-associated antigen-1 (LFA-1) on the 
leukocytes. Both ICAM-1 and LFA-1 are important for the adhesion of leukocytes on the 
endothelial cells. (Fiorucci et al., 2005) 
Studies also showed that H2S decreased expression of the pro-inflammatory markers: TLR 4, 
TNF α, C-C chemokine receptor type 5, INF γ, IL 2,(Zhu et al., 2012), IL-1B, IL6 and IL 8 
(Mariggio et al., 1998; C. Yang et al., 2011)In the same time it increased IL-10 with its potent 
anti-inflammatory features(Esechie et al., 2008) and scavenged and reduced the production of the 
tissue destructing ROS (Yang et al., 2011) The activation of NF-κB a key step in many 
inflammatory responses. Once activated, NF-κB initiates the cascade of pro inflammatory gene 
up-regulation for synthesis of many inflammatory cytokines and chemokines. H2S was proven to 
 inhibit or suppress the activation of NF-κB in many experiments (using different H2S donors) 
and hence decrease the inflammation induced by lipo polysaccharide induced oxidative stress 
(Li, Whiteman, Guan, Neo, Cheng, Lee, Zhao, Baskar, Tan, & Moore, 2008b; Li et al., 2007a).  
Interestingly that in other experiments H2S was noted to enhance the inflammatory reaction 
through NF-κB dependent and independent pathways to act as a pro-inflammatory agent (Ang, 
Moochhala, MacAry, & Bhatia, 2011; Stuhlmeier, Broll, & Iliev, 2009). It might be the balance 
in H2S levels that determines the line between being pro-inflammatory, neutral or anti-
inflammatory. This balance is between the level of H2S and the events the tissue is going 
through. 
 
1.9.5.Mitochondria Protection Effects of H2S  
Mitochondria is not only the main factory of energy in cells, it is also the pace maker of cell 
death (Foo, Mani, & Kitsis, 2005; Kroemer, Galluzzi, & Brenner, 2007). Cytochrome c oxidase, 
an important enzyme in the respiratory electron transport chain of the cell. As the respiratory 
chain occurs within the mitochondria cytochrome C oxidase also is localized in the 
mitochondrial membrane. Cytochrome C oxidase is one of the intracellular targets for H2S 
actions. Its inhibition by H2S was found to be the key step in H2S lethal toxicity and also the 
main step in inducing what is called the suspended animation state in some animals (Cooper & 
Brown, 2008; Hill et al., 1984). 
During the oxidative stress, Ca++ and ROS accumulate within the cell. Once the mitochondrial 
permeability transition pore (MPTP) allows the Ca++ to enter the mitochondria, this large amount 
of Ca++ leads to destruction of the mitochondria. Rather than synthesize of ATP the MPTP 
causes mitochondria to break down leading later on to cell death. Many pathways have been 
proposed to prove and explain the protective effect of H2S on mitochondria. H2S improves the 
mitochondrial respiration recovery rate, increases complex I and complex II efficiency and 
reduces the mitochondrial swelling during IRI (Elrod et al., 2007b). 
When Elrod et al (2007) isolated mitochondria from murin hearts and exposed it to in vitro 
hypoxia assay for 30 min. The group treated with 10uM H2S showed a 67% recovery of 
respiration rate while the vehicle one showed only 36% recovery (Elrod et al., 2007b). He also 
(Elrod et al., 2007b) assessed the mitochondrial function in vivo mice model of IRI in which a 
 group was treated with H2S 50uM/kg at the start of reperfusion. The isolated mitochondria of the 
H2S treated group significantly showed higher rate Oxygen consumption when analyzed for both 
complex I and complex II efficiency. Also electron microscopy showed less swelling in the 
mitochondria of H2S treated group. 
Another important mechanism of H2S protection to the mitochondria is by blocking the 
mitochondrial permeability transition pore (MPTP). Shanmuganathan et al. studied the role of 
the MPTP as a target of cardio protection. Using cyclosporine A, (a known inhibitor of MPTP) at 
the onset of re-oxygenation did protect human myocardium against lethal hypoxia–re-
oxygenation injury. That proved that protecting the mitochondria protects the myocardium from 
IRI and makes it an interesting target for treating much cardiovascular disease. 
Other important role for H2S within the mitochondria during IRI is the up regulation of ROS 
scavengers SOD and GSH, and decreasing levels of reactive oxygen species (ROS). ATP is a 
major source of cell energy. The hydrolysis of the phosphate bonds results in energy release from 
the ATP molecule. Majority of ATP is produced in the mitochondria with the remaining amount 
produced in the cytosol via glycolysis and phosphorylation. H2S also act as a supply for ATP 
during hypoxia, as it was found to improve mitochondrial ATP production during hypoxia in 
SMCs (M. Fu, Zhang, Wu, Yang, Li, & Wang, 2012a). 
For that H2S does not only reduce metabolic demand significantly, it also act as an energy 
substrate to maintain ATP production in hypoxic conditions (Guo et al., 2012b). Mitochondrial 
ATP production showed to improve with H2S in SMCs with Hypoxia induced impaired ATP 
production (Guo et al., 2012a). It has been demonstrated that H2S metabolism in the 
Mitochondria slows the metabolic rate and during hypoxia it improves ATP production (M. Fu, 
Zhang, Wu, Yang, Li, & Wang, 2012b). 
 
1.10.H2S Donor molecules 
The use of H2S donor molecules has enabled the study of H2S on different species, tissues, cells 
or reactions. Unfortunately the use of H2S as a gas is limited by the hazardous potential of its 
toxicity. The inability to sustain a precisely controlled concentration was also a limiting feature. 
These H2S releasing compounds (H2S Donors) had some draw backs and limitations that pushed 
 scientists to invent some new compounds to meet the experiments' need. H2S donors can be 
subdivided according to the following categories which will be discussed in detail further:  
 
a. Natural:  
Inorganic or Organic (Plant or organo sulphur compounds) 
 
b. Synesthetic 
Agonists of H2S -synthesized enzymes. 
Cysteine activated donors 
H2S -releasing drug hybrids 
 
Slow releasing donors 
1. Non-Mitochondrial 
2. Mitochondria-targeted Donors. 
  
 1.10.1.Natural 
a. Inorganic donors 
The two most often used salts NaHS and Na2S, are among the simplest donors still used in H2S 
research. The release of H2S from these molecules is immediate. As these salts rapidly release 
large amounts of short lasting H2S. This pulse release most of the time does not mimic the 
endogenous small amount and prolonged slow release of H2S. These types of donors might 
expose some tissues to a rapid increase in H2S to induce some adverse response instead of 
benefit. This might be part of the explanation behind the controversies in exogenous H2S 
divergent results in some studies. 
Other important inorganic donors are the precursors used in endogenous H2S synthesis, N-acetyl 
cysteine, L-cysteine and D-cysteine are considered and used in research as a source of H2S 
introduction. These precursors when enhanced can significantly increase H2S to with the 
catalysis of CSE and CBS. One of the use of theses precursors is that their increased production 
in our bodies has minimal side effects. 
 
 b. Organic: Organo Sulfar Compounds (OSC) 
Garlic has been used as a natural medicine since long time in many cultures. Garlic derived OSC 
were found responsible for most of the therapeutic potentials of garlic. 
These compounds including diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide 
(DATS), S-propargyl-cysteine & S-allylcysteine were studied extensively in the last few years 
due to its anti-inflammatory and anti-cancer potential. 
 
1.10.2.Synesthetic H2S Donors 
Recently many H2S donors have been invented in order to study H2S effects with more 
utilization of its function and more control of its release and concentration. 
 
a. Cysteine activated H2S donors 
Other synesthetic H2S donors are the cysteine activated Donors. These enzymes are based on the 
N- (benzoylthio) benzamide template. Their H2S release is controlled by cysteine, which its 
availability in different tissues is variable. As recommended by the inventors, the use of these 
cysteine dependent donors might need the addition of cysteine in some tissues that are deficient 
in cysteine (Zhao, 2011). 
 
b. H2S-Releasing Drug Hybrids 
Just like when NO gained its popularity, scientists were tempted by the cytoprotective properties 
of H2S and successfully invented some H2S releasing drug hybrids. These are different from NO 
releasing drug hybrids in terms of better efficacy and safety profile (About-Mohamed, et al., 
2004).  
The main reason found behind the less toxicity induced by the H2S hybrids (compared to the NO 
hybrids) were related to the ability of H2S to inactivate superoxide by the formation of GSH. The 
use of dithiolethione moiety was involved in the synthesis of the majority of these H2S hybrids 
which releases H2S much slower than most of the known H2S donors. And hence not affecting 
the mitochondrial respiration (Li, et al., 2007; Giustarini, et al., 2010). 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are potent medications used to subside 
inflammation and pain associated with many diseases. The use of NSAIDs is still limited by its 
significant side effects, such as gastric ulcers, platelet dysfunction, asthma exacerbation, acute 
renal failure and heart failure. These compounds share the magnified anti-inflammatory of 
NSAIDs as well as H2S while adding the advantage of H2S other cytoprotective mechanisms. 
The invention of these derivatives was based on the evidence behind the H2S potent effect in 
preventing leukocyte adherence to the endothelium opposing the adverse effect of 
cyclooxygenase COX inhibitors (Grander, 1992). The leukocyte adherence to the vessels 
endothelium was found to play a major role in the NSAIDs induced gastric mucosal injury 
(Wallace, et al., 1993; Wallace, 2000). These H2S releasing derivatives like when used on rats 
did not show gastric damage unlike the case with the NSAIDs alone (Wallace, et al., 2007).  
In fact these derivatives showed to have more potent anti-inflammatory effects than the currently 
used NSAIDs (Fiorucci et al., 2007; Li et al., 2007b). And as most of the other H2S donors, the 
effect of using these NSAID derivatives donors showed protective role against IRI (Rossoni et 
al., 2008). Mesalamine derived ATB 429, Naproxen derived ATB 346 and Diclofenac derived 
ATB 337 are some of the known hybrids that showed the success of this combination. Other 
hybrids are being studied in different fields of medicine like, H2S -donating sildenafil (ACS 6), 
H2S -donating latanoprost (ACS 67) for glaucoma treatment and H2S-donating levodopa (ACS 
84) for Parkinson's disease. 
 
c. Slow releasing H2S Donors 
1. Non Mitochondria-targeted H2S Donors 
The release of endogenous H2S from cells is likely to occur in a slower rate of release with less 
amounts than that from sulfide salts, and therefore sulfide salts may not mimic the biological 
effects of naturally produced H2S (Li, Whiteman, Guan, Neo, Cheng, Lee, Zhao, Baskar, Tan, & 
Moore, 2008a; Whiteman et al., 2010). The synthesis of slow releasing H2S donors served this 
interest of mimicking the real biological release of H2S. Also serves the fact that slow release 
might prevent or atleast limit the toxic effects of H2S on mitochondrial respiration (Li et al., 
2007a).  
 
 GYY 4137 Also known as morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate. 
This Lawesson's derivative compound achieved the purpose of its invention, sustaining a 
prolonged slow release of H2S (Lee, et al., 2011). This synthetic molecules is capable of 
releasing H2S over extended periods of time, in small amounts, more like physiological 
endogenous H2S release. The H2S released from GYY4137 was reported to peak at 6 to 10 
minutes and to remain raised for over 180 min. (Li et al., 2008) 
GYY4137 proved its efficacy as a H2S slow donor in many experiments as antihypertensive with 
effects on the vessels walls and blocking the k channels, as an anti-inflammatory (Burguera, 
Vela-Anero, Magalhaes, Meijide-Failde, & Blanco, 2014), as an anti-cancer agent. GYY4137, a 
hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through 
blocking the STAT3 pathway as an anti-atherosclerosis agent (Liu et al., 2013). More relevant to 
this thesis GYY4137 was proven to protect the mitochondria and limit the cytotoxicity induced 
by oxidative stress. In IRI GYY4137 proved in Ex vivo kidney and heart preservation to be 
protective (Li et al., 2008a). 
 
2. Mitochondria Targeted H2S Donors 
Being a key intracellular organelle with major control on many critical cellular functions, the 
mitochondria have attracted researchers in efforts to gain some control over its function. 
Recently a novel H2S donor was created, with the advantage of targeting the mitochondria and 
releasing H2S in a slow and steady manner. 
This novel invention was based on using mitochondria targeting molecules like 
Triphenylphosphonium (TPP+) linked together with H2S moiety dithiolethione or 
thiohydroxybenzamide. TPP is one of the lipophilic cations with highly positive charges 
attracted to the negative membrane potential inside the mitochondria and taken up 
comprehensively and rapidly by the mitochondria in vivo, by that it can carry its attached 
molecules (selective small molecules) through the mitochondrial membrane.  
The H2S moiety dithiolethione or thiohydroxybenzamide are derivatives of non-steroidal anti-
inflammatory drugs used in these novel H2S donors are characterized by their slow and steady 
release of H2S. Dithiolethione have been shown to produce H2S in vivo and provide potent anti-
inflammatory results (Kashfi, 2013; Giustarini, et al., 2010). Being able to ‘target’ mitochondria 
 and limit the oxidative stress mediated by the mitochondria have given these molecules a 
considerable potential advantage.  
In the current project we used AP39 (10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol-5-yl )phenoxy) 
decyl) triphenylphosphonium bromide) which was generously given to us by Dr. Matthew 
Whiteman from University of Exeter Medical School, United Kingdom (Le Trionnaire, et al., 
2014) produces an overall yield of 73% using Phosphonium salt prepared from 10-
bromodecanoic acid and triphenylphosphine under reflux conditions in acetonitrile 33 and 
coupled, using standard carbodiimide conditions, to 5-(4-hydroxyphenyl)- 3H-1,2-dithiole-3-
thione 2). Final purification of AP39 was achieved using flash chromatography on silica gel 
(eluting with methanol), the product forming a crisp foam (which could be handled as a solid) on 
removal of the solvent. 
The novel H2S donor AP39 generates H2S at physiological pH more rapidly and more efficiently 
than GYY4137 and more important is its location of release within the mitochondria. What 
makes mitochondrial targeted donors interesting is that they target the power horse of the cell 
(the mitochondria). When the inventors of these mitochondrial targeted H2S donors compared it 
to the non-mitochondrial slow releasing donors GYY4137 and AP72, they found that the 
mitochondrial donors were more potent in preventing oxidative stress injury in human brain 
micro vascular endothelial cells (HMEC). 
The effect of AP39 was tested in some recent studies and proved to produce cytoprotective and 
antioxidant effects during oxidative stress. Pretreatment with AP39 of murine microvascular 
endothelial cells exposed to oxidative stress, attenuated the production of superoxide by the 
mitochondria, damage to the mitochondrial DNA and bioenergetics dysfunction. Worth 
mentioning is that AP39 stimulated the mitochondrial electron transport and cellular function at 
low concentration and had an inhibitory effect at the higher concentrations (more than 300nM) 
(Szczesny et al., 2014). 
Mitochondrial targeted donors AP39 and AP123 were compared to non targeted donors 
GYY4137, AP67 and AP72 in an assessment of their cytoprotective role against oxidative stress 
toxicity (Le Trionnaire, et al., 2013). The trial used Human brain micro vascular endothelial cells 
(HMEC) and exposed it to a mixture of oxidants including H2O2. ROS generation, mitochondrial 
membrane potential (ΔΨm), mitochondrial ATP synthesis and caspase3/7 activity were all 
assessed in different samples. Cell viability was significantly preserved by GYY4137 and AP72 
 (100-500μM) after treatment with oxidative stress agents. However, the potency was 
substantially increased by targeting mitochondria with AP39 and AP123 (<100nM). The collapse 
of ΔΨm normally observed in oxidative stress conditions was inhibited by all SRHDs.  
Overall "ROS" generation was markedly decreased after treatment with SRHDs. Only AP72 was 
able to inhibit the activation of caspase 3 after treatment with staurosporine/etoposide, but all 
compounds inhibited caspase-3/7 activity. Finally, pre-treatment of HMEC with SRHDs 
preserved ATP generation after treatment with rotenone. These data suggest that SRHDs can 
inhibit/reverse oxidative stress-mediated cellular injury, and highlight the increased potency of 
the mitochondria- targeting H2S donors AP39 and AP123 compared to GYY4137 and AP72. 
Strategies increasing H2S bioavailability, in particular targeting mitochondria, may represent a 
new therapeutic opportunity to limit mitochondrial dysfunction. 
 
 
 
 
 
1.11.Rationale, Objectives and Hypothesis 
 
1.11.1.Rationale 
The mitochondria is the cellular organelle that controls metabolism, energy production (ATP) 
and cell death, and hence, the introduction of H2S -with its protective effects against hypoxia re-
oxygenation- within the mitochondria will theoretically increase the cell resistance to death or 
injury. With this theory in mind mitochondria targeted H2S (AP39) should be more potent than 
the other widely used H2S donor GYY4137. 
Recently the slow releasing H2S donors gained interest -being more physiological- (both AP39 
and GYY4137 are slow releasing donors). While AP39 as a mitochondria targeted donor, 
 showed protective results in hypoxia re-oxygenation in endothelial cells in it was never studied 
in renal cells.  
Renal tubular epithelial cells are the most vulnerable renal cells to hypoxia, and hence protecting 
them from IRI may impact kidney injury limitation. 
 
1.11.2.Objectives 
1- Identify the effect of AP39 on IRI in renal tubular epithelial cells. 
2- Compare the effect of AP39 to those of GYY4137 (most used H2S donor lately)  
3- Identify the mechanism behind the protective effects of AP39 on cellular levels. 
 
1.11.3.Hypothesis 
"We hypothesized that AP39 will have significant protective effects against hypoxia re-
oxygenation when added to the porcine renal tubular epithelial cells (LLC PK1) in-vitro. Also 
AP39 will result in superior cell protective effects to GYY4137 after 24 hours of hypoxia 
followed by 24 hours re-oxygenation". 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2 
2.Methodology 
2.1.Experimental Design 
2.1.1.Cell Culturing: 
All of the steps of work in preparing the cells or the experiment plates were done in the cell 
culturing chamber under aseptic technique. Porcine Kidney Epithelial cells PK1(ATCC 
Georgetown University Washington DC USA) was the cell line used for all the in vitro 
experiments due to their availability, affordability, ease of culture and most importantly that they 
represents one of the most important cells affected in the kidney tissue by IRI. Cells were grown 
in a size 75 cm3 flasks with 15-20 ml of Media 199 (GIBCO@lifetechnologies.IncCarlsbad, 
Calif., north of San Diego. USA) supplemented by 10% Fetal Bovine Solution (FBS) and 1% 
Penicillin/streptomycin solution (Modified Media 199).  
Flasks were incubates in a cell incubator with physiological pH, 37˚ C Temperature, 95% air, 5% 
CO2 and Ultra violet (UV) sterilization. Culturing media was changed every 48hrs to allow for 
nutrient supply and removal of metabolic waste. When confluence of the cells reached 80 - 90%, 
cells were split and used to prepare wells for experiments. 
 
2.1.2.Cell preparation for experiments: 
When cells became 70-90 % confluent, they were washed with 10ml phosphate buffer solution 
(PBS). PBS is aspirated and then 700uL of 0.25% trypsin is added, and flask was tilted to each 
side so that trypsin to cover the bottom of the cell. Flasks incubated for 3-5 minutes then 10 ml 
of media is added to the flasks to mix with the trypsin and the detached cells then aspirated into a 
15 ml test tube and centrifuged for 5 min in a speed of 500 /m. 
Trypsenized media is aspirated away and cells pellet is re-suspended in Media 199. Amount of 
media added is according to the desired number of wells to be prepared and number of cells 
desired for each well. Cells were plated in 12 well plates with surface area of 3.7cm2 and volume 
capacity of 6.76ml with 50-80 x 104 cell/ml, in each well we put 1ml of cells in the modified 
media 199 (Media 199 with 10 % Fetal Bovine Serum FBS and 1% of penicillin streptomycin 
mix).  
 Minimum of 2 plates were prepared, one to be used as "Normoxia samples" and another one 
exposed to IR "Hypoxia samples". Plates were stored in the cell incubator for a period of 1-2 
days until the cells were confluent. Experiments are started when wells were 70-80% confluent 
(see Experiments section below).  
Both Normoxia samples and Hypoxia samples shared the same number of wells and both shared 
the same number of control samples (media alone) as well as treatment samples (media + H2S 
donor). Control samples in Normoxia samples were used as the standard to define toxic doses of 
the treatment, while control samples in Hypoxia samples used to define the extent of hypoxia on 
the cells and in comparison with treatment samples used to define the benefit or harm of the 
treatment dose used. 
 
2.1.3.Ischemia Reperfusion in Vitro model 
a. Hypoxia (IRI) 
Culturing media (modified media 199) was aspirated from the wells (when plates are confluent) 
leaving the adherent cells ready for new media. DMEM (glucose and FBS free media) 1 ml was 
used for each well in the Hypoxia samples plates with or without treatment. Cells were placed in 
the Hypoxia chamber device (HypOxystation H85, info@hypoxygen.us,) which allowed us to 
control temperature and concentration of Oxygen (O2), Carbon Dioxide (CO2) and Nitrogen (N). 
The Hypoxia chamber was set to a temperature of 37˚C, O2 concentration of 1%, CO2 of 5% and 
N of 94% with a compact gas control system to maintain gases concentration as set all the time. 
The Hypoxia samples plates were placed in the hypoxia chamber when it reached the preset 
temperature and oxygen concentration and was kept there for 24 hours. Being in Hypoxia as well 
as nutrients free media simulated the ischemic condition whereas the subsequent washing of cells 
and reconstituting in modified medium 199 1ml was added to each well with then plates then 
placed in the cell culturing incubator for 24 hours at 37˚C, room air, simulating Reperfusion/re-
oxygenation). 
The reason why 24 hours was used as the target time of hypoxia was based on the observation 
that 20 hours did not seem to be efficient enough to reduce cell viability in the Control samples 
to less than 50% (inadequate cell injury) while 28 hours and more showed a reduction of 
viability down to less than 10% ( too much cell injury). 
  
b. Normoxia 
Plates Modified Media 199 1 ml was used for each well with or without treatment. The 
Normoxia samples plates are placed in the cell culturing incubator (air concentrations of O2 and 
CO2) for 24 hours then 1ml of modified Media 199 was added to each well and plates were 
returned to cell culturing incubator to complete the 48 hours of the experiment. 
The treatment samples were prepared by using the desired concentration of the treatment (AP39 
or GYY4137) mixed in the media (modified Media 199 in Normoxia samples and DMEM in 
Hypoxia samples) to form a solution for each desired concentration, then 1 ml of the prepared 
solution was added to the corresponding labeled well in either Normoxia or Hypoxia samples.  
 
AP39: This compound was generously donated by Dr. Matthew Whiteman for the purposes of 
these experiments. (Peninsula Medical School, Exeter University, Genetics of complex Traits, 
Institute of Biomedical and Clinical science, St Luke's Campus, Magdalen Rd, Exeter,). Figure 2. 
The solid form (small crystals) (Molecular weight: 721.7692) was diluted in Dimethyl sulfoxide 
(DMSO) in a concentration of 20uM as a stock solution and stored immediately in -80˚C for one 
time use without refreezing. AP39 stock solution was then used depending on how many 
samples (number of wells or milliliters) and desired concentration (desired dose). 
Example: When 4 samples (4 ml) of 200 nM of AP39 is needed the formula C1 V1 = C2 V2 was 
used 200nM x 4000 uL = 20000nM (stock solution concentration) x V2 
 V2= 200 x 4000 / 20000 = 40uL in 4 mL of media 
 
GYY 4137: (Cayman Chemical Company, Ann Arbor, Michigan. USA) solid form (powder) 
(MW: 311.14) was diluted in Dimethyl sulfoxide (DMSO) in a concentration of 4mM as a stock 
solution and stored immediately in -80˚C for one time use without refreezing.  Figure 3. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure of AP39 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structure of GYY4137 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4 Different groups of cells or samples of cells. 
 
 
 
 
 
 
 
 
 
 
 2.1.4.Viability Assay Reactive Oxygen Species Assay 
To detect the percentage of viable, Necrotic, Apoptotic and Late apoptosis early necrosis cells as 
well as ROS, Flow cytometry was used after staining the samples with 7-ADD (7-AAD; Bio 
Legend, San Diego, CA), Annexin V (Annexin V; Bio Legend, San Diego, CA) and DHR123 as 
detailed in sections below. 
 
2.1.5.Cell preparation for Flow cytometer 
Contents of each well were transferred into flow cytometer tubes labeled and grouped in 
correspondence to the wells. Each well was washed with PBS, then 200 uL of 0.25% trypsin was 
added to each well and allowed to act on detaching the cells off the wells for 3-5 min in the 
incubator. 1ml of modified Media 199 was added to each well then each well content was 
transferred into its corresponding flow cytometer tube. 
Flow cytometer tubes were run in the centrifuging machine for 5 min with a speed of 500x g. 
The cells pellets formed in the bottom of the tubes were re-suspended with 1 ml of PBS. Then 
again tubes are run in the centrifuge machine for the same period of time on the same speed. 
Finally cells were re-suspended by adding 100uL of 1x Annexin V Buffer solution (needed for 
the Apoptosis stain Annexin V and DHR 123). Then 1 microliter of Annexin V stain and 3 
microliters of 7AAD stain were added to each sample but one of the stains in each of the heat 
killed containing tubes (heat killed cells were prepared from one of the Normoxia samples by 
keeping the cells in a heat block for 10min in 60˚C) labeled as control for each 7-AAD and 
Annexin V. 
Flow Tubes were stored in the dark for 10 min then 400uL of 1x Annexin V Buffer solution was 
added (to reach the minimum 500uL sample volume needed for Flow cytometer) before running 
the tubes in the flow machine.  
 
Same cell preparation steps for flow cytometry detailed in the section above were followed, 
Instead of staining the samples with viability stains, 25uM of DHR 123 was used to stain all 
samples except for the unstained sample (used for voltage setting). Flow tubes were stored in the 
dark for 15 min before adding the remaining 400uL to each tube before running it in the flow 
cytometer. 
  
2.1.6.Flow cytometer 
After washing the cells and staining it as described in the preparation step, samples were 
analyzed by flow cytometry using the Beckman Coulter FC 500 flow cytometer (Beckman 
Coulter Canada LP, Mississauga, ON). Using the two laser excitation wavelengths, 488 and 633. 
FL2-572 BP filter was used for PE Annexin V as well as DHR 123 (in a separate run and 
different samples) while FL4- 675 filter was used for 7AAD. Number of events setting was set 
for maximum of 5000 and voltage and compensation settings were set according to the unstained 
samples. 
For viability tests unstained samples, heat killed cells stained with Annexin V or 7AAD (positive 
control) were used to set the compensation and voltage to determine viabile cells in the 
experiment samples.  
 
2.1.7.Quantitative RT-PCR analysis 
a. RNA isolation: 
In preparation for quantitative RT- PCR, RNA isolation from the plates was done using Ribozol 
(Ribozol ; AMRESCO, LLC. 6681 Cochran Road Solon, OH 44139 USA) to lyse the cells then 
stored at -80˚C until later were the Ribozol product protocol was followed to complete the 
isolation of RNA. 
 
b. DNA synthesis 
Following RNA isolation, Nano drop technology was used to evaluate the concentration and the 
quality of RNA. Super Script II Reverse Transcriptase (Invitrogen, Inc.) was used together with 
Oligo(dT) 12–18 primers following the product protocol. The cDNA concentration and quality was 
measured by the Nano drop technology as well before performing the PCR step. Isolated RNA 
and cDNA had a 260/280 ratings >1.9.  
 
 
 c. qPCR analysis 
Apoptosis represented the most significant cell death pattern that was reduced by the H2S donors, 
for that the genes selected were those mainly known to be anti apoptotic or pro-apoptotic to 
determine if any explains the protective effects of these H2S donors.  
Primer-BLAST software (NCBI) was used to design the primer sequences. Primers used are 
BCL2-associated X protein (BAX), mitogen-activated protein kinase 1 (MAPK1), BH3 
interacting domain death agonist (BID), B-cell CLL/lymphoma 2 (BCL2) and hypoxanthine 
ribosyltransferase (HPRT-1), Fold-change in gene expression was calculated via the ΔΔCt 
method, using HPRT-1 as a reference gene. SYBR Green PCR Master Mix (Quanta Biosciences 
Inc.) was used for all the cDNA samples. Analysis was done using the StepOnePlus Real-Time 
PCR thermal cycler and software package (Applied Biosystems Inc.). Primers were purchased 
from Life technologies Inc. Burlington, ON. Canada and are listed in Table 1. 
 
2.2.Statistical analysis 
Statistical analysis was performed with (GraphPad Software, Inc. 7825 Fay Avenue, Suite 230 
La Jolla, CA 92037 USA) using the ANOVA for independent groups. Statistical significance 
was accepted at p< 0.05. Data are presented according to the mean ± standard deviation (SD) in 
all figures and tables.  
 
 
 Table 1: Primer Details 
MAPK1 
Forward primer AAACCTTCCAACCTGCTGCT 
Reverse primer GACTTGGTGTAGCCCTTGGAAT 
 
Bcl 2 
Forward primer AGGATAACGGAGGCTGGGATG 
Reverse primer TATGGCCCAGATAGGCACCC 
 
BAX 
Forward primer CCCTTTTGCTTCAGGGGATGA 
Reverse primer CCGCCACTCGGAAAAAGACT 
 
BID 
Forward primer GGATTCTAAGGTCAGCAACGGT 
Reverse primer ATCGATTGCCGTCTGTCTGC 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3 
3.Results 
The objectives of the current study were to evaluate role of H2S donors in protecting porcine 
kidney epithelial cells from the injury induced by hypoxia and re-oxygenation.  
In our in vitro model we were able to induce this injury and asses its effects on the viability of 
LLC PK1 cells. We were also able to assess the percentage of the different forms of cell death 
that occur due to this injury. Flow cytometry using the known florescent stains (7AAD and 
Annexin IV) used to assess cell viability, necrosis, apoptosis and late apoptosis early necrosis are 
interpreted below.  
 
3.1.Cells Viability After Hypoxia re-oxygenation injury 
3.1.1.Control (Non Treated Cells) Viability 
We exposed LLC PK1 cells to hypoxia for 24hr followed by re-oxygenation for 24hr then 
examined cell viability using flow cytometry. Cell viability decreased to 27% (SD +/- 13.1) in 
samples without any treatment (control) when compared to Normoxia cells that was kept for 
48hr in normal culturing conditions (Viability of 82 % (SD +/- 6.2). The difference was 
statistically significant (P<0.01) 
Figure (5 and 6). 
 
3.1.2.AP39 Protective Effects on Cells Viability 
Targeting the cells with AP39 at concentrations of 200nM added 10 minutes before exposing the 
cells to hypoxia maintained cell viability above 79% (SD +/- 10) after 24hr of hypoxia followed 
by 24hr of re-oxygenation. This protective effect was statistically significant (P<0.01) in 
comparison to the control samples (without any treatment). When compared to Normoxia 
samples, AP39 treated cells exposed to hypoxia re-oxygenation showed a viability which is 
nearly the same and statistically showed no significant difference indicating the potent protective 
effects of AP39 against hypoxia re-oxygenation. Figures (5, 6 and 7). 
 
 3.1.3.GYY4137 Protective Effects on Cells Viability 
The non- Mitochondrial donor GYY4137 at concentrations 200-500nM maintained cell viability 
at an average of 43% (SD +/- 30) after hypoxia re-oxygenation. GYY 4137 showed to improve 
the viability of the cells in comparison with the control non treated group exposed to hypoxia re-
oxygenation and the difference was statistically significant (P< 0.02). Figures (5,6 and 7). 
 
3.1.4.Comparison Between AP39 and GYY4137 Protective Effects on Cell 
viability 
AP39 had superior protective results compare to non – mitochondrial H2S donors. The results 
showed no statistical significance between the non-treated Normoxia samples and AP39 treated 
cells (exposed to hypoxia re-oxygenation injury). GYY4137 was not able to achieve this 
statistical non-significant results achieved in the AP39 group when compared to the Normoxia 
samples, even with higher doses reaching up to 500mM. The higher doses of GYY4137 showed 
similar results, but showed toxic effects in non-stress samples (treated by high dose GYY4137 
but in Normoxia conditions). Figures (6 and 7). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: Flow cytometer 2-D Plot analysis of all treatment groups: A) Control samples 
exposed to hypoxia re-oxygenation, B) AP39 200nM treated samples exposed to hypoxia re-
oxygenation, C) GYY4137 200nM treated samples exposed to hypoxia re-oxygenation, D) 
Normoxia samples Not exposed to hypoxia. The color represent cell population 
concentration: red represents maximum cell concentration while blue the least.  The screen 
in each flow cytometer figure above is divided to four quarters labeled E1-4:  E1 present 
Necrosis, E2: Late apoptosis early necrosis, E3: Viable tissue and E4: Apoptosis. All based 
on the detection of the two viability stains 7AAD and Annexin V. 
The figure reflects the improvement in cell viability in the H2S treated samples in 
comparison to control samples. Even after hypoxia re-oxygenation exposure AP39 treated 
samples showed similar viability to the non-stressed Normoxia samples. 
. 
  
 
 
 
 
 
 
 
 
 
Figure 6: Cell viability after hypoxia re-oxygenation with 200nM AP39 and 200nM 
GYY4137 compared to control (hypoxia re-oxygenation samples without treatment) and to 
Normoxia (non-stressed samples without treatment). Multiple comparison of the Standard 
deviation of groups using one way anova: Statistical significance exist when compared to 
the Control samples P<0.01.  Statistical significance exist when compared to the 
Normoxia samples P<0.01.  Each treatment group had an average n= 7. Bars on top of each 
samples column represent the Standard of Error for the column. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 7: Cell viability after hypoxia re-oxygenation with different doses of AP39 and 
200nM GYY4137 compared to control (hypoxia re-oxygenation samples without treatment) 
and to Normoxia (non-stressed samples without treatment). Multiple comparison of the 
Standard deviation of groups using one way anova: Statistical significance exist when 
compared to the Control samples P<0.01.  Statistical significance exist when compared to 
the Normoxia samples P<0.01. The analysis above reflect the best dose identified for both 
AP39 and GYY4137 (200nM). Each treatment group had an average n= 5 based on 
repeated experements. Bars on top of each samples column represent the Standard of 
Error for the column. 
 
 3.2.Mitochondria-targeted H2S donor reduces Apoptosis, 
Necrosis and Late Apoptosis early Necrosis  
Analysis of the different forms of cell death detected by using flow cytometry with different 
donors of H2S- showed interesting results. Detailed results discussed below. 
 
3.2.1.Control Cells Death Forms 
In the Control cells after hypoxia re-oxygenation, most of the non-viable cells were shifted 
towards the apoptosis axis (Annexin V marker uptake) indicating an apoptosis of around 48% 
(SD +/- 6.5) Figure (6). Very few percentage of cells 1.5% (SD +/- 2) where in the necrosis axis 
(7AAD marker uptake) Figure (8), while the late apoptosis early necrosis axis (uptake of both 
Annexin V and 7AAD) constituted up to 28% (SD +/- 16) of the non-viable cells, Figure (7). 
Compared to apoptosis <13% (SD +/- 12) in the Normoxia cells, the increase in apoptosis in 
control cells after hypoxia re-oxygenation was almost near 4 times the Normoxia, which was 
statistically significant Figure (6). Both necrosis and late apoptosis early necrosis percentage 
doubled in the control cells compared to the Normoxia cells Figure (7 and 8). 
 
3.2.2.AP39 Effects on Cell Death Forms 
Cells treated with AP39 200nM had a significant drop in apoptosis to as low as 14% (SD +/- 8) 
which when compared to the control samples and Normoxia cells showed statistical significance 
and non-significance respectively Figure (6). AP39 dropped cell late apoptosis early necrosis to 
6.8% (SD +/- 5) compared to 28.6% (SD +/- 16) in the control group that showed statistical 
significance with a P< 0.01 Figure (9). Necrosis was significantly reduced when cells were 
treated with AP39 200nM to show a statistical significance when compared to the control 
samples and non-significance when compared to the Normoxia samples, Figure (8). 
 
3.2.3.GYY4137 Effects on Cell Death Forms 
GYY4137 did significantly decrease Necrosis when compared to the control. There was no 
significant difference when comparing Necrosis percentage in Normoxia and GYY4137 treated 
samples Figure (10). GYY4137 also significantly decreased the percent of late apoptosis early 
 necrosis in comparison to the control samples and with no statistical significance when compared 
to the Normoxia samples Figure (9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8: Analysis of percentage of apoptotic cells after hypoxia re-oxygenation with 
200nM AP39 and 200nM GYY4137 compared to control (hypoxia re-oxygenation samples 
without treatment) and to Normoxia (non-stressed samples without 
treatment). Statistical significance exist when compared to the Control samples (P<0.01). 
 Statistical significance exist when compared to the Normoxia samples (P<0.01). Each 
treatment group had an average n= 5 based on repeated experements. Bars on top of each 
samples column represent the Standard of Error for the column. 
 
 
 
 
 
 
 
 
 
  
Figure 9: Analysis of percentage of late apoptosis early necrosis cells after hypoxia re-
oxygenation with 200nM AP39 and 200nM GYY4137 compared to control (hypoxia re-
oxygenation samples without treatment) and to Normoxia (non-stressed samples without 
treatment). Statistical significance exist when compared to the Control samples (P<0.01). 
 Statistical significance exist when compared to the Normoxia samples (P<0.01). Each 
treatment group had an average n= 5 based on repeated experements.  Bars on top of each 
samples column represent the Standard of Error for the column. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 10: Analysis of percentage of necrotic cells after hypoxia re-oxygenation with 
200nM AP39 and 200nM GYY4137 compared to control (hypoxia re-oxygenation samples 
without treatment) and to Normoxia (non-stressed samples without 
treatment). Statistical significance exist when compared to the Control samples (P<0.01). 
 Statistical significance exist when compared to the Normoxia samples (P<0.01). Each 
treatment group had an average n= 5 based on repeated experements.  Bars on top of each 
samples column represent the Standard of Error for the column. 
 
 
 
 
 
 
 
 
 
 
  
 
3.3.Mitochondria Targeted H2S Donor decreased the reactive 
oxygen species 
Part of the work on identifying the important mechanisms by which the mitochondria targeted 
H2S defend the cells more effectively than the non-targeted donors, amount of ROS produced 
within the cells were analyzed using the flow cytometer to detect the florescent stain DHR123 
which is activated in the presence of ROS. 
In the control group ROS was evident up to 78% with a mean of 75 % (SD +/- 3.5) and detected 
on flow cytometer. While Normoxia samples in culturing environment (non stress conditions) 
had maximum of 15% (SD +/- 2.6). Difference was statistically significant between the 2samples 
(P<0.01) Figure (10). In the AP39 200nM treated cells, the amount of ROS was 33.5% with a 
mean of 34.8% (SD +/- 1.25). Results were statistically significant when compared to the control 
cells (P<0.01). GYY4137 dose of 200nM (that was effective in overall viability) did not induce 
any reduction in ROS and showed similar amount of ROS without any significant difference 
when compared to the control sample (Figure 11 and Figure 12). 
 
 
  
Figure 11: Flow cytometer Histogram Plot analysis for the detection of ROS in different 
treatment samples: A) Control samples exposed to hypoxia re-oxygenation, B) AP39 
200nM treated samples exposed to hypoxia re-oxygenation, C) GYY4137 200nM treated 
samples exposed to hypoxia re-oxygenation, D) Normoxia samples (Not exposed to hypoxia 
and without treatment). All based on the detection of Rhodamine 123. The figure reflects 
the reduction of ROS in the AP39 samples in comparison to control samples but no 
reduction in GYY4137 samples. 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 12: Percent of ROS detected by Flow cytometry after hypoxia re-oxygenation with 
200nM AP39 and 200nM GYY4137 compared to control (hypoxia re-oxygenation samples 
without treatment) and to Normoxia (non-stressed samples without 
treatment). Statistical significance exist when compared to the Control samples P<0.01. 
 Statistical significance exist when compared to the Normoxia samples P<0.01. Each 
treatment group had an average n= 4 . 
 Bars on top of each samples column represent the Standard of Error for the column. 
 
 
 
  
3.4.Evaluation of Apoptosis Related Genes  
Further work to define the mechanisms behind the difference in potency between AP39 and 
GYY4137 in protecting LL PK1 cells from hypoxia re-oxygenation injury, we used the real time 
q PCR analysis. Since apoptosis was most prominiant cell death pathway in hypoxix re-
oxygenation injury and most remarkably prevented by H2S donors we focused on some common 
genes known to play a role in the control of apoptosis and mitochondria protecting mechanisms. 
The genes tested were: Bid (BH3-interacting domain death agonist), Bax (Bcl-2-associated X 
protein), BCL2 (apoptosis regulating gene by controlling the mitochondrial membrane 
permeability) and MAPK (regulates cell signals in responses to stress). 
In the Control samples Both Bid and Bax dropped significantly after the hypoxia re-oxygenation 
stress compare to the non-stressed Normoxia group. While both MAPK and BCL2 showed 
marked amplification, the increase in MAPK was more significant Figure (13).  
When AP39 treated cells were compared to control and Normoxia samples, AP39 fully 
prevented the drop in Bax and prevented the increase in MAPK in comparison to the control 
samples and more in favor towards the Normoxia samples. Changes in Bid and BCL2 were not 
as obvious as the other tested genes, however the increase in BCL2 was slightly higher than the 
Normoxia samples but not as high as the control samples. 
In the GYY4137 treated samples, It slightly limited the drop in Bax when compared to the 
control samples but definitely not as much as the treatment with AP39 did, that was also the case 
in MAPK were it did increase more than the AP39 samples but not as high as the control 
samples. GYY4137 treatment showed changes that is opposite to the Normoxia group in Bid and 
more similar to the control in BCL2 (Figure 13). 
 
 
 
 
  
Figure 13: PCR results reflecting the expression of various genes involved in apoptosis. The 
zero point in the fold change axis represent the level of gene expression in Normoxia 
samples. Bid gene expression was reduced in both H2S treatment samples but more in 
GYY4137 samples, Bax and Bcl2 increased in both H2S treatment samples. MAPK 
decreased in the AP39 but increased slightly in the GYY4137 samples. 
All samples had average of n=5. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4 
4.Discussion 
 
Delayed graft function is a major limiting factor in kidney transplantation which has a significant 
effect on both the short and long term outcome of the graft. It is commonly accepted that one of 
the major contributors to DGF is IRI. Several studies have demonstrated the efficacy of H2S in 
protecting various tissues during IRI including heart, brain and muscle. We have recently shown 
that H2S not only protects the kidney during cold IRI, but it also has a protective effect against 
warm IRI associated with transplantation in both short and long term on animal studies (Lobb, et 
al., 2012; Lobb, et al., 2014). 
The importance of mitochondria as an organelle with a major role in energy production and cell 
death has always received a significant amount of interest from those studying IRI. In fact, H2S 
has been shown in several studies to have multiple protective roles including its role as a 
potential donor of electrons in the electron transport chain, and thus contributing to ATP 
synthesis. Other protective benefits are by reducing ROS induced mitochondrial damage and 
limiting the mitochondrial membrane permeability.  
Recently, mitochondria targeted H2S donors have been created and have shown promising 
protective effects during oxidative stress in human endothelial cells, however, these donors have 
not yet been tested on renal cells. Here we compared these mitochondria targeted donors with 
one of the widely accepted H2S donors GYY4137 (due to its slow releasing mechanism that 
simulates the physiological production of H2S in the body).  
The H2S donor AP39 (one of few mitochondria-targeted H2S donors) showed to be protective 
against IRI in our study. As shown in figure (5) the addition of AP39 was able to improve cell 
viability following IRI as well as significantly reducing cell apoptosis as shown in figure (8). 
Previous studies on AP39 showed its initial efficacy in protecting murine brain microvascular 
endothelial cells from oxidative stress (Szczesny et al., 2014) 
Our study showed that introducing H2S donors targeting the mitochondria during the ischemic 
phase of IRI protected the renal tubular epithelial cells from the harmful cascades during both 
ischemia and reperfusion injuries. The potent protective effect of the mitochondria targeting H2S 
donor AP39 was superior to that of the non-mitochondria targeting H2S donor GYY4137. We 
 believe this study is the 1st study to show the efficacy of AP39 on protecting kidney tubular 
epithelial cells from hypoxia re-oxygenation.  
Our study showed that 200nM of AP39 achieved the best protective effects which is within the 
same range (50-300nM) used in Szczesny's (Szczesny et al., 2014), however, the dose that 
showed best results in our study was 200nM. Variability might be due to the use of different cell 
line and different species with different sensitivity and metabolism of H2S and the degree and 
mechanism of the oxidative stress we used. 
The ischemia reperfusion model we used has the advantage of being a non-chemical real hypoxia 
stress using the high efficiency hypoxia chamber, assuring the maintenance of 1% O2 
concentration during the entire hypoxia phase of the experiment as well as humidity and sterility. 
We also noted that previous studies on LLC-PK1 using chemical or enzymatic methods of 
ischemia showed a disagreement on the time of hypoxia needed to induce sufficient injury in 
different studies (Wiegele, Brandis, & Zimmerhackl, 1998); (Ueda, Kaushal, Hong, & Shah, 
1998)(Hotter, Palacios, & Sola, 2004).  
A disadvantage of such a model when compared to the chemical and enzyme induced IRI is the 
longer duration needed for cell injury in the hypoxia chamber.(Kurian & Pemaih, 2014) This was 
the only disadvantage reported by Kurian et al. on the same cell line where they tested the effects 
of NaSH (Rapid releasing H2S donors) on three different models using chemical, enzyme or 
chambers to induce IRI. However they noted that 12hr ischemia was not enough to induce more 
than 50% injury in the chamber model.(Kurian & Pemaih, 2014) they stated that the hypoxia 
chamber type of hypoxia requires more time of exposure to induce significant damage.  
In our study we did achieve significant cell injury after 20 - 24hr. When cells were exposed to < 
20hr of hypoxia, the injury was not able to induce enough cell death, at least not consistent as the 
24hr. Specially with the increased number of passages on cultured cells their ability to tolerate 
<20hr of hypoxia was higher. When cells were exposed to  28hr or more of hypoxia, some 
samples showed a near 100% cell death which affects the ability to notice some of the effects of 
different treatments as well as the chance for reversibility or worsening of the injury during re-
oxygenation.  
Despite the different available H2S donors in the field, GYY4137 has the advantage of being a 
slow releasing H2S donor which we believe is needed for its effects to last as long as possible in 
such long periods of warm hypoxia which is also more physiological (Li, Salto-Tellez, Tan, 
 Whiteman, & Moore, 2009). Previously used H2S such as NaHS and Na2S were noted to release 
large amounts of H2S as fast boluses which may induce toxic, less lasting effect and less 
physiological. 
Ling Li et al showed the benefits of using a slow H2S releasing donor such as GYY4137 over the 
inorganic H2S donors as NaHS. GYY4137 did not show the cytotoxic, cell cycle altering effects 
or apoptosis that were shown with NaHS on cultured rat vascular smooth muscle cells. Excessive 
and rapid release of H2S (when NaHS was used) initiated a cascade of signaling pathways that 
results in cell death. Concluding that slow build up to low concentrations of H2S is more 
physiological and can improve cell viability in vivo which is simulated by the use of slow 
releasing H2S donors. While the cytotoxic effects or pro-apoptotic effects occurs when high 
concentrations of H2S build up over a short period of time simulated by the use of inorganic 
rapid releasing H2S donors. 
Interestingly GYY4137 was shown to induce vasorelaxation that can drop the blood pressure and 
might be of concern if used in humans. It will be of interest to evaluate the effects of AP39 on 
similar studies to see if its effective dose affects the blood pressure or not. In the current study, 
we chose to use porcine renal tubular epithelial cells due to their multiple advantages. Other than 
being easy to culture and affordable, renal tubular epithelial cells are the most sensitive cells in 
the kidney to ischemia. Due to the function of ion transport they require a high metabolic rate but 
their ability to function in anaerobic glycolysis is limited.  
Using a glucose and serum free media during the hypoxia phase and switching back to glucose 
and serum rich media during reperfusion simulates the more clinical scenario where cells are 
deprived of energy sources during hypoxia then regain those during reperfusion. This way of 
alteration in media to simulate the real ischemia reperfusion situation was previously used and 
showed efficacy during in vitro studies (Jiang, Liu, Luo, & Dong, 2010). The fact that AP39 
targets the mitochondria and releases H2S there, supports the hypothesis that AP39 protective 
effects were significantly more potent than GYY4137 when equal doses were used. AP39 was 
superior in results even when we used higher doses (50 – 500uM) of GYY4137 that was used 
previously in our lab and in published in-vitro work.  
We found that the effects of AP39 on improving cell viability during IRI was superior by at least 
20%. Our working hypothesis was that AP39 releases H2S at the level of the mitochondria where 
it is utilized as a source of ATP, albeit inefficient, and works to provide a protective effect during 
 oxidative stress. Unfortunately this action is not yet fully understood. Given that the majority of 
cell death in vertebrates is thought to be through the mitochondrial pathway of apoptosis (Green 
& Kroemer, 2004) and these signal pathways are of significant importance in the pathogenesis of 
many ischemia related disease, (Thompson, 1995) we believe that our data support a novel 
therapeutic application for H2S donors, particularly ones that are targeted to the mitochondria. 
Among renal diseases, the first description of apoptosis was in 1987 in an animal model of 
hydronephrosis (Gobe & Axelsen, 1987). IRI was noted to significantly increase apoptosis and 
remarkably more in kidneys with delayed graft function (Oberbauer, Rohrmoser, Regele, 
Muhlbacher, & Mayer, 1999). These early studies clearly point to the important role of apoptosis 
in IRI and that controlling it or reducing it may contribute to an improvement in the outcome of 
kidney as well as other solid organ transplants. 
Both H2S donors in our study successfully improved cell viability by reducing all apoptosis, 
necrosis and late apoptosis early necrosis, but the reduction in apoptosis by AP39 was 
exceptional. AP39 reduced apoptotic cells to a level similar to that of Normoxia (not exposed to 
IRI) samples without any statistical significant difference between the two. Some studies have 
used both Annexin V and 7AAD to define Late apoptosis early necrosis cells as necroptosis with 
or without the addition of a RIP1 inhibitor that blocks necroptosis pathway with necrostatin-
1(Nec-1) or TUNNEL staining (Pan et al., 2014)(Ch'en, Tsau, Molkentin, Komatsu, & Hedrick, 
2011). Whether all such cells were truly reflected as necroptosis or late apoptosis early necrosis 
or late apoptosis, it is still reduced with both donors significantly. 
To further understand the protective mechanism behind AP39’s effects against hypoxia re-
oxygenation in renal tubular epithelial cells, we evaluated the reduction of ROS. The reduction 
of ROS was evident by at least 20% and 5% in the AP39 and GYY4137 respectively when 
compared to the control group. Considering the hazardous effects of these ROS on the 
mitochondria and the entire cell, explains that even a minor reduction in such molecules can 
explain part of the protective effect of these donors. The test we used for ROS detection, the 
DHR123 assay is considered the best effective probe used in human granulocytes as flow 
cytometric assessment of the oxidative burst (Walrand et al., 2003), and is also known to be 
highly sensitive to H2O2. 
Superoxide is formed first in the inner mitochondrial membrane at the electron transport chain 
(ETC) I and III by a transfer of a free electron to molecular oxygen. The mitochondrial enzymes 
 then reacts with it to form H2O2. In the presence of GSH the enzyme glutathione peroxidase 
(GSPx) converts H2O2 to water as a defense against ROS. (Boveris & Chance, 1973); (Turrens & 
Boveris, 1980); (Turrens, Freeman, Levitt, & Crapo, 1982) 
To some extent H2O2 is known to be less reactive than superoxide, while the latest is known to 
be produced more by the mitochondria (Quinlan, Perevoschikova, Goncalves, Hey-Mogensen, & 
Brand, 2013). Despite the fact that both H2S donors were able to protect the cells from hypoxia 
re-oxygenation, the amount of persistent DHR123 signals on flow was still significant. This 
reflects the presence of less reactive amounts of ROS (like H2O2) that induces a positive signal 
but insufficient or of less reactivity (not like superoxide) to induce injury. 
Whether AP39 and GYY4137 reduced the production of ROS or consumed the ROS produced 
during this hypoxia was not addressed in our study. When Shen et al. did western blots on human 
umbilical vein endothelial cells (HUVECs) after an in vitro IRI in both NaHS treated cells and 
compared it to control, NaHS increased Bcl2 (anti-apoptotic protein) but decreased Bax as well 
as many other pro-apoptotic proteins like Caspase 3 and 9 (Shen et al., 2013). In a non IRI model 
where NaHS was added to lung fibroblasts cells, the anti-apoptotic Bcl2 protein was not 
unregulated, which reflects the different effect of H2S on Bcl2 in normal versus IRI conditions. 
(Baskar, Li, & Moore, 2007) Many other mechanisms of H2S protection of the mitochondria 
have previously been shown including modification of the action potential, electron donor, 
stimulant of electron transport in the mitochondria (Wang, 2012) attenuation of homocysteine 
induced toxicity (Kamat, Kalani, Tyagi, & Tyagi, 2014) or Inhibition of Ca++ induced 
mitochondrial permeability transition pores. 
As our study was focusing on the effect of targeting the mitochondria by this new H2S donor 
during IRI, selecting members of the family of Bcl-2 proteins was chosen due to its known role 
in apoptosis. The Bcl-2 is the prototype member of a family of proteins containing at least one 
Bcl-2 homology (BH) region. Based on the classification of the family of Bcl-2 proteins for 
classification we selected a major anti-apoptotic protein like Bcl-2 and pro-apoptotic 
multidomain proteins: Bax and Bad (De Marchi et al., 2004).  
Previously some studies showed that Bax expression was associated with DNA fragmentation 
and induction of apoptosis (Lasso, et al., 2007). However De Marchi et al showed that blocking 
the Bcl-2 family pro-apoptotic proteins like Bax does not fully protect the mitochondria and that 
mitochondria can still be permeabilized by inducing a permeability transition PT such as high 
 intra cellular Ca2, hexokinase/VDAC-dependent mechanism and other mechanisms. (Majewski 
et al., 2004)(Kroemer, Galluzzi, & Brenner, 2007) Also in another study Bax did not show any 
changes in an ex vivo model on rat cerebral cortex after 24 hypoxia neither alone nor after re-
oxygenation of hypoxia followed by oxygenation (Hu et al., 2003). The renal tubular cells of 
human kidneys also did not show any difference in Bax expression in Oberbauer R et.al study. 
These authors studied biopsy samples from transplanted kidneys from cadaveric donors with 
evidence of ischemic injury and apoptosis and compared it to biopsies from well-functioning 
kidneys of living donation with significantly less apoptosis (Oberbauer et al., 1999). 
In our study there was an unexpected increase expression of the gene of this pro-apoptotic 
protein Bax in the AP39 treated samples. Normally Bax and Bid are cytosolic proteins but once 
apoptosis signals are initiated both of these proteins start to form supramolecular openings or 
bind to the permeability transition pore complex (PTPC) to release proteins from the inter 
membrane space (IMS) of the mitochondria leading to cell death (Kroemer et al., 2007). 
Knowing the role of Bax a reasonable explanation for its rise in the AP39 group might indicate 
that AP39 does not inhibit the apoptosis initiating signals (hence transcription of Bax is 
overexpressed), instead it inactivates the cascade that leads to apoptosis by inactivating Bax, 
This inactivation of Bax might be leading to a persistent transcription of its gene in order to get 
the usual feedback inhibition (that is accomplished by an active Bax) that shuts down the 
apoptosis signaling mechanism or perhaps cell death. Also another possible explanation is that a 
number of other molecules are known to bind to the pro-apoptotic proteins when formed 
and inhibit their function. For example, 14-3-3e a molecule known to prevent Bad from 
translocation to the mitochondria and it also sequestrates Bax in the cytosol (Kroemer et al., 
2007). Along with the Bcl-2 family, Ca2 and some chemotherapeutic agents (Brenner & Grimm, 
2006) showed to affect the PTPC opening which supports the theory of another pathway other 
than the pro apoptotic genes tested in LLC-PK1 cells.  
IRI is no doubt much more complex than being represented by an in vitro hypoxia re-
oxygenation model, but hypoxia re-oxygenation is the most important role player in initiating 
many cascades responsible for the full picture of IRI. Modulating the hypoxia re-oxygenation 
factor will continue to be of major research interest. The exact cellular hypoxia re-oxygenation 
conditions in real IRI in the living tissues are difficult if ever possible to be exactly simulated in 
an in vitro experiment. 
 Our study shows clearly that AP39 has a potent protective effect on renal tubular cells against 
hypoxia re-oxygenation as well as its superiority when compared to GYY4137. Further in vitro 
work should consider looking into the amount, duration and peak of H2S released after AP39 and 
compare it to that released from similar doses of GYY4137. That might add more explanation to 
the comparison, however, the potent protective effects of AP39 was not challenged with even 
higher doses of GYY4137. 
Our data suggests that AP39 is a viable candidate for ex vivo studies aiming to avoid the cold 
injury that is applied as a concept of organ storage. However there is no reason why AP39 cannot 
be of benefit in cold hypoxia re-oxygenation injury trials. Also in vivo experiments on animal 
models of kidney IRI or transplant will remain an essential step for the transition of the use of 
such H2S donor in the clinical practice to assure its safety and efficacy. 
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